Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + 1-(beta-D-ribofuranosyl)-nicotinamide
ADP + beta-nicotinamide D-ribonucleotide
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
ATP + a protein
ADP + phosphorylated protein
ATP + acidic alpha-syntrophin protein
ADP + acidic alpha-syntrophin phosphoprotein
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + ADAQHATPPKKKRKVEDPKDF
ADP + ADAQHAT(P)PPKKKRKVEDPKDF
-
a histone peptide substrate
-
-
?
ATP + ADP-ribosylation factor GTPase activating protein 3 protein
ADP + ADP-ribosylation factor GTPase activating protein 3 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + AE binding protein 2 protein
ADP + AE binding protein 2 phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + amphiphysin I
ADP + phosphorylated amphiphysin
-
-
-
?
ATP + APEX nuclease protein
ADP + APEX nuclease phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + ARAF serine/threonine protein kinase protein
ADP + ARAF serine/threonine protein kinase phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + ATRIP protein
ADP + ATRIP phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + axonal cytoskeleton protein
ADP + phosphorylated axonal cytoskeleton protein
ATP + B-cell lymphoma protein 2
ADP + phosphorylated B-cell lymphoma protein 2
-
B-cell lymphoma protein 2 is phosphorylated at Ser70, Cdk5-mediated B-cell lymphoma protein 2 phosphorylation is pivotal for the antiapoptotic effect of Bcl-2 and contributes to the maintenance of neuronal survival by Cdk5
-
-
?
ATP + biotin-TVSEESNVLCLSKSPNKHNRLYMKARPFF
ADP + biotin-TVSEESNVLCLSKpSPNKHNRLYMKARPFF
-
-
phosphorylated on Ser595
-
?
ATP + bloom syndrome helicase
ADP + phosphorylated bloom syndrome helicase
ATP + Bni4
ADP + phosphorylated Bni4
-
-
-
-
?
ATP + Boi1
ADP + phosphorylated Boi1
-
-
-
-
?
ATP + Boi2
ADP + phosphorylated Boi2
-
-
-
-
?
ATP + BRCA2
ADP + phosphorylated BRCA2
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
ATP + C-terminal domain of RNA polymerase II
ADP + phosphorylated C-terminal domain of RNA polymerase II
ATP + CAK
ADP + phosphorylated CAK
-
substrate of cyclin-dependent kinase cdk7
-
-
?
ATP + CALD1 protein
ADP + CALD1 phosphoprotein
-
reccombinant human GST-tagged substrate, with CDK6
-
-
?
ATP + cAMP responsive element binding protein 3-like 2 protein
ADP + cAMP responsive element binding protein 3-like 2 phosphoprotein
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + casein
ADP + phosphorylated casein
-
-
-
?
ATP + CCAAT/enhancer binding protein gamma protein
ADP + CCAAT/enhancer binding protein gamma phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + cdc2
ADP + phosphorylated cdc2
phosphorylation of Thr161
-
-
?
ATP + cdc2 PK
ADP + phosphorylated cdc2 PK
-
substrate of cyclin-dependent kinase activating kinase CAK
-
-
?
ATP + cdc2-like protein
ADP + phosphorylated cdc2-like protein from Caenorhabditis in chimeric complexes including both mitotic and G1/S cyclins
from Caenorhabditis in chimeric complexes including both mitotic and G1/S cyclins
-
-
?
ATP + Cdc20
ADP + phosphorylated Cdc20
ATP + Cdc6
ADP + phosphorylated Cdc6
ATP + CDK1
ADP + phosphorylated CDK1
-
CDK7 phosphorylates the activation segment or T-loop of CDK1
-
-
?
ATP + Cdk1
ADP + phosphorylated Cdk2
-
Cdk7
-
-
?
ATP + cdk2
ADP + phosphorylated cdk2
ATP + CDK9
ADP + phosphorylated CDK9
-
-
-
?
ATP + Clb6
ADP + phosphorylated Clb6
-
-
-
-
?
ATP + Cln3 protein
ADP + Cln3 phosphoprotein
ATP + coiled-coil domain protein 52 protein
ADP + coiled-coil domain protein 52 phosphoprotein
-
substrate of cyclin E/CDK2, not of cyclinA/CDK2
-
-
?
ATP + collapsing response mediator protein
ADP + phosphorylated collapsing response mediator protein
-
-
-
-
?
ATP + CPEB-associated factor Maskin protein
ADP + CPEB-associated factor Maskin phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + Cprk
ADP + phosphorylated Cprk
-
i.e. Cdk5/p35-regulated kinase
-
-
?
ATP + CREB-binding protein
ADP + phosphorylated CREB-binding protein
-
-
-
-
?
ATP + cyclin dependent kinase 2
ADP + phosphorylated cyclin dependent kinase 2
-
cyclin activating kinase CAK phosphorylates Thr160 of cdk2, a prerequisite for cell cycle control
-
-
?
ATP + cyclin H protein
ADP + cyclin H phosphoprotein
-
CDK8
-
-
?
ATP + cyclin-dependent kinase
ADP + phosphorylated cyclin-dependent kinase
-
-
-
?
ATP + Dab1 protein
ADP + Dab1 phosphoprotein
ATP + dephosphin
ADP + phosphorylated dephosphin
ATP + diacylglycerol kinase epsilon protein
ADP + diacylglycerol kinase epsilon phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + diphthamide biosynthesis protein 2 isoform a protein
ADP + diphthamide biosynthesis protein 2 isoform a phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + distal-less homeobox 1 isoform 1 protein
ADP + distal-less homeobox 1 isoform 1 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + DNA polymerase alpha
ADP + phosphorylated DNA polymerase alpha
-
-
-
-
?
ATP + DNA polymerase sigma
ADP + phosphorylated DNA polymerase sigma
-
-
-
-
?
ATP + dopamine
ADP + phosphorylated dopamine
-
phosphorylation by cdk5
-
-
?
ATP + dopamine and cAMP-regulated phosphoprotein
ADP + phosphorylated dopamine and cAMP-regulated phosphoprotein
-
i.e. DARPP-32, phosphorylation by cdk5 at Thr75 and Thr34
-
-
?
ATP + dynamin I
ADP + phosphorylated dynamin
-
-
-
?
ATP + E2F1 protein
ADP + E2F1 phosphoprotein
-
CDK8
-
-
?
ATP + early mitotic inhibitor 1 protein
ADP + early mitotic inhibitor 1 phosphoprotein
ATP + ephexin 1
ADP + phosphorylated ephexin 1
-
-
-
-
?
ATP + ErbB2
ADP + phosphorylated ErbB2
ATP + ErbB3
ADP + phosphorylated ErbB3
ATP + Erp1/emi2 protein
ADP + Erp1/emi2 phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + establishment of cohesion-1 homologue 2 protein
ADP + establishment of cohesion-1 homologue 2 phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + estrogen receptor
ADP + phosphorylated estrogen receptor
-
Cdk2 phosphorylation at Ser104 and Ser106
-
-
?
ATP + ETS variant gene-1 protein
ADP + ETS variant gene-1 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + eukaryotic elongation factor 2
ADP + phosphorylated eukaryotic elongation factor 2
ATP + ezrin
ADP + phosphorylated ezrin
-
phosphorylation by cdk5 at Thr235 in the NH2-terminal region and consequent dissociation of Rho GDP dissociation inhibitor from an ezrin/Rho-GDI complex
-
-
?
ATP + Fin1
ADP + phosphorylated Fin1
-
-
-
-
?
ATP + Fizzy1 protein
ADP + Fizzy1 phosphoprotein
-
substrate of cyclin E/CDK2, not of cyclinA/CDK2
-
-
?
ATP + Fkh2p
ADP + phosphorylated Fkh2p
ATP + Gcn4 protein
ADP + phosphorylated Gcn4 protein
-
-
-
?
ATP + Glc8 protein
ADP + phosphorylated Glc8 protein
-
-
-
?
ATP + glucocorticoid receptor
ADP + dephosphorylated glucocorticoid receptor
-
CDK5 phosphorylates glucocorticoid receptor at multiple serines, including Ser203 and Ser211 of its N-terminal domain, and suppresses the transcriptional activity of this receptor on glucocorticoid-responsive promoters by attenuating attraction of transcriptional cofactors to DNA
-
-
?
ATP + glucocorticoid receptor
ADP + phosphorylated glucocorticoid receptor
ATP + glycogenin protein
ADP + glycogenin phosphoprotein
-
substrate of cyclin B/CDK1, not of cyclinA/CDK2
-
-
?
ATP + granulin isoform 1 precursor protein
ADP + granulin isoform 1 precursor phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + Gsy2 protein
ADP + phosphorylated Gsy2 protein
-
-
-
?
ATP + heat shock transcription factor 1 protein
ADP + heat shock transcription factor 1 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + Hermes protein
ADP + Hermes phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + HHASPRK
ADP + HHAS(P)PRK
-
-
-
-
?
ATP + HHASPRK
ADP + phosphorylated HHASPRK
-
-
-
-
?
ATP + high-molecular-weight neurofilament
ADP + phosphorylated high-molecular-weight neurofilament
-
-
-
?
ATP + histone 1
ADP + phosphorylated histone 1
ATP + histone deacetylase 6 protein
ADP + histone deacetylase 6 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + histone H1
ADP + dephosphorylated hiostone H1
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
ATP + histone H1
ADP + phosphorylated steroid histone H1
-
-
-
-
?
ATP + histone H1-derived peptide
ADP + histone H1-derived peptide phosphate
-
-
-
-
?
ATP + histone H3 protein
ADP + histone H3 phosphoprotein
-
CDK8
-
-
?
ATP + histone stem-loop binding protein
ADP + histone stem-loop binding phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + human cytomegalovirus tegument protein pp65
ADP + phosphorylated human cytomegalovirus tegument protein pp65
-
-
-
-
?
ATP + huntingtin
ADP + phosphorylated huntingtin
ATP + Kunitz type serine protease inhibitor 2 protein
ADP + Kunitz type serine protease inhibitor 2 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + lamina-associated protein 2-beta isoform protein
ADP + lamina-associated protein 2-beta isoform phosphoprotein
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + LOC222229 protein
ADP + LOC222229 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + low density lipoprotein receptor adaptor protein 1 protein
ADP + low density lipoprotein receptor adaptor protein 1 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + MAP/microtubule affinity regulating kinase 3 protein
ADP + MAP/microtubule affinity regulating kinase 3 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + MAP1B
ADP + phosphorylated MAP1B
ATP + MAP2
ADP + phosphorylated MAP2
-
-
-
-
?
ATP + maternal embryonic leucine zipper kinase protein
ADP + maternal embryonic leucine zipper kinase phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + Mcm3
ADP + phosphorylated Mcm3
-
-
-
-
?
ATP + Mcm4
ADP + phosphorylated Mcm4
-
-
-
-
?
ATP + Med13 protein
ADP + Med13 phosphoprotein
-
CDK8
-
-
?
ATP + MEF2
ADP + phosphorylated MEF2
-
-
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
ATP + MEP50 protein
ADP + MEP50 phosphoprotein
ATP + MGC86234 protein
ADP + MGC86234 phosphoprotein
-
i.e. potassium channel tetramerisation domaincontaining 3, substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + microtubule-associated tau
ADP + phosphorylated microtubule-associated tau
-
-
-
?
ATP + mini-chromosomemaintenance protein 2
ADP + phosphorylated mini-chromosomemaintenance protein 2
-
-
-
-
?
ATP + mini-chromosomemaintenance protein 3
ADP + phosphorylated mini-chromosomemaintenance protein 3
-
-
-
-
?
ATP + mini-chromosomemaintenance protein 4
ADP + phosphorylated mini-chromosomemaintenance protein 4
-
-
-
-
?
ATP + mini-chromosomemaintenance protein 5
ADP + phosphorylated mini-chromosomemaintenance protein 5
-
-
-
-
?
ATP + mini-chromosomemaintenance protein 6
ADP + phosphorylated mini-chromosomemaintenance protein 6
-
-
-
-
?
ATP + mini-chromosomemaintenance protein 7
ADP + phosphorylated mini-chromosomemaintenance protein 7
-
-
-
-
?
ATP + minor histocompatibility antigen HA-1 protein
ADP + minor histocompatibility antigen HA-1 phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + Munc-18
ADP + phosphorylated Munc-18
ATP + neuregulin receptor ErbB2
ADP + phosphorylated neuregulin receptor ErbB2
ATP + neuregulin receptor ErbB3
ADP + phosphorylated neuregulin receptor ErbB3
ATP + neurofilament heavy chain
ADP + phosphorylated neurofilament heavy chain
-
-
-
-
?
ATP + neuronal cytoskeletal protein NF-H
ADP + phosphorylated neuronal cytoskeletal protein NF-H
-
-
-
?
ATP + neuronal cytoskeletal protein tau
ADP + phosphorylated neuronal cytoskeletal protein tau
-
-
-
?
ATP + neuronal cytoskeletal proteins NF-M
ADP + phosphorylated neuronal cytoskeletal protein NF-M
-
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
ATP + NF-H peptide
ADP + phosphorylated NF-H peptide
ATP + NF-M
ADP + phosphorylated NF-M
ATP + NR1 receptor
ADP + phosphorylated NR1 receptor
ATP + NR2 receptor
ADP + phosphorylated NR2 receptor
ATP + Orc2
ADP + phosphorylated Orc2
-
-
-
-
?
ATP + Orc6
ADP + phosphorylated Orc6
-
-
-
-
?
ATP + origin recognition complex 1
ADP + phosphorylated origin recognition complex 1
-
-
-
-
?
ATP + origin recognition complex 2
ADP + phosphorylated origin recognition complex 2
-
-
-
-
?
ATP + origin recognition complex 3
ADP + phosphorylated origin recognition complex 3
-
-
-
-
?
ATP + origin recognition complex 4
ADP + phosphorylated origin recognition complex 4
-
-
-
-
?
ATP + origin recognition complex 5
ADP + phosphorylated origin recognition complex 5
-
-
-
-
?
ATP + origin recognition complex 6
ADP + phosphorylated origin recognition complex 6
-
-
-
-
?
ATP + p35 protein
ADP + p35 phosphoprotein
-
a nuclear transcription factor, Cdk5-p25 phosphorylates p53 on Ser15, Ser33, and Ser44
-
-
?
ATP + Pak1
ADP + phosphorylated Pak1
-
-
-
-
?
ATP + palmitoylated membrane protein 1 protein
ADP + palmitoylated membrane protein 1 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + parkin
ADP + phosphorylated parkin
ATP + PASCIN protein
ADP + PASCIN phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + Pho4 protein
ADP + phosphorylated Pho4 protein
-
-
-
?
ATP + Pho81
ADP + phosphorylated Pho81
-
-
phosphorylated Pho81 is an inhibitor for Pho85
-
?
ATP + phosphatidylinositol-4-phosphate 5-kinase type IIba protein
ADP + phosphatidylinositol-4-phosphate 5-kinase type IIba phosphoprotein
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + PIF1 protein
ADP + PIF1 phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + PKTPKKAKKL
ADP + PKpTPKKAKKL
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
ATP + polymerase II C-terminal domain
ADP + phosphorylated polymerase II C-terminal domain
-
-
-
?
ATP + POM21 protein
ADP + POM21 phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + pre-B-cell leukemia transcription factor 1 protein
ADP + pre-B-cell leukemia transcription factor 1 phosphoprotein
-
substrate of cyclinA/CDK2, not of cyclin B/CDK1
-
-
?
ATP + pre-synaptic P/Q-type voltage-dependent calcium channel
ADP + phosphorylated pre-synaptic P/Q-type voltage-dependent calcium channel
-
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
ATP + promyelocytic leukemia zinc finger
ADP + phosphorylated promyelocytic leukemia zinc finger
can also be phosphorylated by CDK1 albeit in a less efficient fashion than by CDK2
-
-
?
ATP + protein
ADP + phosphoprotein
ATP + protein tau
ADP + protein tau phosphate
ATP + PSD-95
ADP + phosphorylated PSD-95
-
-
-
-
?
ATP + Rad9 protein
ADP + Rad9 phosphoprotein
ATP + RasGRF1
ADP + phosphorylated RasGRF1
-
-
-
-
?
ATP + RasGRF2
ADP + phosphorylated RasGRF2
-
-
-
-
?
ATP + Rb peptide
ADP + Rb phosphopeptide
-
from retinoblastoma-associated protein
-
-
?
ATP + replication factor C
ADP + phosphorylated replication factor C
-
-
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
ATP + retinoblastoma protein
ADP + retinoblastoma phosphoprotein
ATP + retinoblastoma-related protein
ADP + phosphorylated retinoblastoma-related protein
ATP + Rga2
ADP + phosphorylated Rga2
-
-
-
-
?
ATP + Rga2 protein
ADP + phosphorylated Rga2 protein
-
-
-
?
ATP + RhoGEF Tus1p
ADP + phosphorylated RhoGEF Tus1p
ATP + Rim 15 protein
ADP + phosphorylated Rim15 protein
-
-
-
?
ATP + RNA polymerase 1 protein
ADP + RNA polymerase 1 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
ATP + RNA polymerase II C-terminal domain
ADP + phosphorylated RNA polymerase II C-terminal domain
ATP + RNA polymerase II C-terminal domain protein
ADP + RNA polymerase II C-terminal domain phosphoprotein
-
-
-
-
?
ATP + RNA polymerase II carboxy-terminal domain
ADP + phosphorylated RNA polymerase II carboxy-terminal domain
-
CDK8
-
-
?
ATP + RNA polymerase II largest subunit
ADP + phosphorylated RNA polymerase II largest subunit
specifically hyperphosphorylates the carboxyl-terminal
-
-
?
ATP + Rvs167 protein
ADP + phosphorylated Rvs167 protein
-
-
-
?
ATP + RXL motif-containing peptide
ADP + RXL motif-containing phosphopeptide
-
peptide sequence corresponding to amino acids 866-880 of RNA polymerase II C-terminal domain. Substrate phosphorylation by CDK6 with K-cyclin from Kaposi sarcoma herpesvirus, but addition of this peptide significantly reduces substrate phosphorylation by cyclin E-CDK2 and cyclin D2-CDK6
-
-
?
ATP + SCR-1
ADP + phosphorylated SCR-1
ATP + SEC14-like 1 isoform a protein
ADP + SEC14-like 1 isoform a phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + semaphorin 6D protein
ADP + semaphorin 6D phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + Sept5 protein
ADP + phosphorylated Sept5 protein
-
Sept5 protein is phosphorylated at Ser17
-
-
?
ATP + septine 5
ADP + phosphorylated septine 5
ATP + Sic1
ADP + phosphorylated Sic1
ATP + Sic1 protein
ADP + phosphorylated Sic1 protein
-
-
-
?
ATP + similar to bicaudal C homologue 1 protein
ADP + similar to bicaudal C homologue 1 phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + similar to peroxisomal biogenesis factor 5 protein
ADP + similar to peroxisomal biogenesis factor 5 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + similar to Trigger of mitotic entry 1 protein
ADP + similar to Trigger of mitotic entry 1 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + similar to Zinc finger protein 516 protein
ADP + similar to Zinc finger protein 516 phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + SIRT2
ADP + phosphorylated SIRT2
-
-
-
?
ATP + SMAD protein
ADP + SMAD phosphoprotein
-
CDK8
-
-
?
ATP + SMARCD2/BAF60:SWI/SNF-related matrix-associated actin-dependent regulator of chromatin d2 protein
ADP + SMARCD2/BAF60:SWI/SNF-related matrix-associated actin-dependent regulator of chromatin d2 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + SmcX-Jumonji/ARID domain-containing protein 1C protein
ADP + SmcX-Jumonji/ARID domain-containing protein 1C phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
ATP + STAT3 protein
ADP + STAT3 phosphoprotein
-
Cdk5 phosphorylates at Ser727
-
-
?
ATP + STAU2
ADP + phosphorylated STAU2
ATP + steroid receptor coactivator-1
ADP + phosphorylated steroid receptor coactivator-1
-
-
-
-
?
ATP + steroidogenic factor 1
ADP + phosphorylated steroidogenic factor 1
ATP + striatin protein
ADP + striatin phosphoprotein
-
substrate of cyclin E/CDK2, not of cyclinA/CDK2
-
-
?
ATP + Swi5
ADP + phosphorylated Swi5
-
-
-
-
?
ATP + Swi6
ADP + phosphorylated Swi6
-
substrate of cdc28p
-
-
?
ATP + synaptojanin I
ADP + phosphorylated synaptojanin I
-
-
-
?
ATP + syntaxin-1
ADP + phosphorylated syntaxin-1
ATP + T-cell protein tyrosine phosphatase
ADP + phosphorylated T-cell protein tyrosine phosphatase
ATP + TATA box-binding protein-associated factor 2F protein
ADP + TATA box-binding protein-associated factor 2F phosphoprotein
-
substrate of cyclin B/CDK1, not of cyclinA/CDK2
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
ATP + Tau protein
ADP + Tau phosphoprotein
ATP + telomeric repeat binding factor 2 protein
ADP + telomeric repeat binding factor 2 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + Tipin protein
ADP + Tipin phosphoprotein
-
substrate of cyclinA/CDK2 and cyclin E/CDK2
-
-
?
ATP + tumor suppressor Rb
ADP + phosphorylated tumor suppressor Rb
-
-
-
-
?
ATP + v-raf murine sarcoma viral oncogene homolog B1 protein
ADP + v-raf murine sarcoma viraloncogene homolog B1 phosphoprotein
-
substrate of cyclin B/CDK1 and cyclinA/CDK2
-
-
?
ATP + Vac17
ADP + phosphorylated Vac17
-
-
-
-
?
ATP + Varicella-Zoster virus IE63 protein
ADP + phosphorylated Varicella-Zoster virus IE63 protein
ATP + VGCC
ADP + phosphorylated NR1 receptor
ATP + WAVE1
ADP + phosphorylated WAVE1
-
-
-
-
?
ATP + Wee1A
ADP + phosphorylated Wee1A
ATP + Whi5 G1 protein
ADP + phosphorylated Whi5 G1 protein
-
-
-
?
ATP + Xenopus laevis protein associated with PRK1 protein
ADP + Xenopus laevis protein associated with PRK1 phosphoprotein
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + zinc finger protein 46 protein
ADP + zinc finger protein 46 phosphoprotein
-
substrate of cyclinA/CDK2, not of cyclin E/CDK2
-
-
?
ATP + [elongation factor 2]
ADP + [elongation factor 2]phosphate
ATP + [tau protein]
ADP + O-phospho-[tau-protein]
ATP + [tau protein]
ADP + [O-phospho-tau protein]
ATP + [tau-protein]
ADP + O-phospho -[tau-protein]
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
N6-PhEt-ATP-gamma-S + 1-deoxy-D-xylulose 5-phosphate reductoisomerase
?
-
gene locus At5g62790
-
-
?
N6-PhEt-ATP-gamma-S + 20S proteasome alpha subunit PAD1
?
-
gene locus At3g51260
-
-
?
N6-PhEt-ATP-gamma-S + 5-methyltetrahydropteroyl-triglutamate-homocysteine methyltransferase
?
-
i.e. EC 2.1.1.14, gene locus At517920
-
-
?
N6-PhEt-ATP-gamma-S + adenosine kinase 1
?
-
gene locus At3g09820
-
-
?
N6-PhEt-ATP-gamma-S + aldehyde dehydrogenase 7B4
?
-
gene locus At1g54100
-
-
?
N6-PhEt-ATP-gamma-S + annexin 1
?
-
gene locus At1g35720
-
-
?
N6-PhEt-ATP-gamma-S + aquaporin interactor
?
-
gene locus At4g38220
-
-
?
N6-PhEt-ATP-gamma-S + beta glucosidase 18
?
-
gene locus At1g52400
-
-
?
N6-PhEt-ATP-gamma-S + fructose-bisphosphate aldolase 2
?
-
gene locus At4g38970
-
-
?
N6-PhEt-ATP-gamma-S + glyceraldehyde-3-phosphate dehydrogenase C2
?
-
gene locus At1g13440
-
-
?
N6-PhEt-ATP-gamma-S + heat shock protein 70
?
-
gene locus At3g09440
-
-
?
N6-PhEt-ATP-gamma-S + isopropylmalate dehydrogenase 1
?
-
gene locus At5g14200
-
-
?
N6-PhEt-ATP-gamma-S + low expression of osmotically responsive genes 2
?
-
gene locus At2g36530
-
-
?
N6-PhEt-ATP-gamma-S + mitochondrial malate dehydrogenase 1
?
-
gene locus At1g53240
-
-
?
N6-PhEt-ATP-gamma-S + NAD(P)-binding Rossmann-fold superfamily protein
?
-
gene locus At5g19440
-
-
?
N6-PhEt-ATP-gamma-S + pfkB-like carbohydrate kinase family protein
?
N6-PhEt-ATP-gamma-S + proline iminopeptidase
?
-
gene locus At2g14260
-
-
?
N6-PhEt-ATP-gamma-S + retinoblastoma related 1 protein
?
-
-
-
-
?
N6-PhEt-ATP-gamma-S + Rubisco activase
?
-
gene locus At2g39730
-
-
?
N6-PhEt-ATP-gamma-S + Sku5 similar 1
?
-
gene locus At4g25240
-
-
?
N6-PhEt-ATP-gamma-S + TatD related DNase
?
-
gene locus At3g52390
-
-
?
N6-PhEt-ATP-gamma-S + thioglucoside glucohydrolase 1
?
-
gene locus At5g26000
-
-
?
additional information
?
-
ATP + a protein
ADP + a phosphoprotein
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
-
cdk2-cyclin A phosphorylates e.g. protein substrate p107 and peptide substrate PKTPKKAKKL, requiring a small hydrophobic patch RXL, known as a recruitment peptide
-
-
?
ATP + a protein
ADP + a phosphoprotein
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
-
-
-
-
?
ATP + a protein
ADP + phosphorylated protein
-
-
-
-
?
ATP + a protein
ADP + phosphorylated protein
-
-
-
-
?
ATP + a protein
ADP + phosphorylated protein
-
-
-
-
?
ATP + axonal cytoskeleton protein
ADP + phosphorylated axonal cytoskeleton protein
-
-
-
-
?
ATP + axonal cytoskeleton protein
ADP + phosphorylated axonal cytoskeleton protein
-
regulated by integrin alpha1beta1
-
-
?
ATP + bloom syndrome helicase
ADP + phosphorylated bloom syndrome helicase
-
-
-
-
?
ATP + bloom syndrome helicase
ADP + phosphorylated bloom syndrome helicase
-
phosphorylation at Ser-714 and Thr-766, both the N- and C-terminal domains are phosphorylated by Cdc2
-
-
?
ATP + BRCA2
ADP + phosphorylated BRCA2
-
phosphorylates at Ser3291, phosphorylation reaches maximal levels in G2/M
-
-
?
ATP + BRCA2
ADP + phosphorylated BRCA2
-
phosphorylates at Ser3291, an event that disrupts association with RAD51
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation at Thr131
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation at Thr131
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation at Thr131
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation at Thr131
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation at Thr131
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation at Thr131
-
-
?
ATP + C-terminal domain of RNA polymerase II
ADP + phosphorylated C-terminal domain of RNA polymerase II
-
-
-
-
?
ATP + C-terminal domain of RNA polymerase II
ADP + phosphorylated C-terminal domain of RNA polymerase II
-
Cdk7 phosphorylates Ser-5 in the heptad repeats of the C-terminal domain of RNA polymerase II, Cdk9 phosphorylates Ser-2 in the C-terminal domain of RNA RNA polymerase II
-
-
?
ATP + C-terminal domain of RNA polymerase II
ADP + phosphorylated C-terminal domain of RNA polymerase II
-
-
-
-
?
ATP + Cdc20
ADP + phosphorylated Cdc20
-
Cdk phosphorylation affects interaction of Cdc20 with Mad2 and the anaphase-promoting complex-cyclosome in HeLa cells
-
-
?
ATP + Cdc20
ADP + phosphorylated Cdc20
-
in vitro substrate of Cdk1 and Cdk2
-
-
?
ATP + Cdc20
ADP + phosphorylated Cdc20
-
substrate of Cdk1, rather than of Cdk2
-
-
?
ATP + Cdc20
ADP + phosphorylated Cdc20
-
in vitro substrate of Cdk1 and Cdk2
-
-
?
ATP + Cdc6
ADP + phosphorylated Cdc6
-
-
-
-
?
ATP + Cdc6
ADP + phosphorylated Cdc6
-
-
-
-
?
ATP + cdk2
ADP + phosphorylated cdk2
-
CDK7 phosphorylates the activation segment or T-loop of CDK2
-
-
?
ATP + cdk2
ADP + phosphorylated cdk2
-
-
-
?
ATP + Cln3 protein
ADP + Cln3 phosphoprotein
-
recombinant His-tagged Cln3 protein is phosphorylated by Pho85/Pho80 complexes at S449 and T520. Cdc28 phosphorylates Cln3 to a greater extent than Pho85, probably because it phosphorylates Cln3 at more sites in the PEST region than Pho85
-
-
?
ATP + Cln3 protein
ADP + Cln3 phosphoprotein
-
recombinant His-tagged Cln3 protein is phosphorylated by Pho85/Pho80 complexes at S449 and T520. Cdc28 phosphorylates Cln3 to a greater extent than Pho85, probably because it phosphorylates Cln3 at more sites in the PEST region than Pho85
-
-
?
ATP + Dab1 protein
ADP + Dab1 phosphoprotein
-
-
-
-
?
ATP + Dab1 protein
ADP + Dab1 phosphoprotein
-
Cdk5-p35 or Cdk5-p39
-
-
?
ATP + dephosphin
ADP + phosphorylated dephosphin
-
-
-
-
?
ATP + dephosphin
ADP + phosphorylated dephosphin
-
Cdk5 regulates endocytosis involving dephosphin activity, overview
-
-
?
ATP + early mitotic inhibitor 1 protein
ADP + early mitotic inhibitor 1 phosphoprotein
-
-
-
-
?
ATP + early mitotic inhibitor 1 protein
ADP + early mitotic inhibitor 1 phosphoprotein
-
i.e. Emi1, is phosphorylated by CDKs in mitotic but not S-phase cell extracts
-
-
?
ATP + ErbB2
ADP + phosphorylated ErbB2
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + ErbB2
ADP + phosphorylated ErbB2
-
phosphorylation at Thr871
-
-
?
ATP + ErbB2
ADP + phosphorylated ErbB2
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + ErbB2
ADP + phosphorylated ErbB2
-
phosphorylation at Thr871
-
-
?
ATP + ErbB3
ADP + phosphorylated ErbB3
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + ErbB3
ADP + phosphorylated ErbB3
-
phosphorylation at Ser1120
-
-
?
ATP + ErbB3
ADP + phosphorylated ErbB3
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + ErbB3
ADP + phosphorylated ErbB3
-
phosphorylation at Ser1120
-
-
?
ATP + eukaryotic elongation factor 2
ADP + phosphorylated eukaryotic elongation factor 2
-
phosphorylation on Ser595 by Cdk2
-
-
?
ATP + eukaryotic elongation factor 2
ADP + phosphorylated eukaryotic elongation factor 2
-
phosphorylation on Ser595 by Cdk2. Substrate mutant S595A is poorly phosphorylated by cyclin A-CDK2
-
-
?
ATP + Fkh2p
ADP + phosphorylated Fkh2p
-
phosphorylation of forkhead transcription factor Fkh2p is part of regulation of cell cycle-specific gene expression, e.g. of the CLB2 cluster, Fkh2p phosphorylation by Cdc28p is regulated by complex formation with Mcm1p and Ndd1p, and phosphorylation, overview
-
-
?
ATP + Fkh2p
ADP + phosphorylated Fkh2p
-
forkhead transcription factor Fkh2p, C-terminally phosphorylation of Fkh2p promotes interaction with the activator Ndd1p, which becomes also phosphorylated, activity with Fkh2p mutants, overview
-
-
?
ATP + glucocorticoid receptor
ADP + phosphorylated glucocorticoid receptor
-
-
-
-
?
ATP + glucocorticoid receptor
ADP + phosphorylated glucocorticoid receptor
-
-
-
-
?
ATP + histone 1
ADP + phosphorylated histone 1
-
-
-
-
?
ATP + histone 1
ADP + phosphorylated histone 1
-
-
-
?
ATP + histone 1
ADP + phosphorylated histone 1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
commercial substrate
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
substrate of CDK11p110
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
substrate of e.g. of cheimeric K-cyclin/cdk6 and K-cyclin-cyclin D2
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
CDK2
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
preferred substrate of cdk5 associated with p35
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
commercial substrate, Cdk5
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
substrate of CDKB
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
substrate of Cdk-A/cyclin D2
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
substrate of Cdk-A/cyclin D2 and of proliferating cell nuclear antigen/cyclin D2
-
-
?
ATP + huntingtin
ADP + phosphorylated huntingtin
-
-
-
?
ATP + huntingtin
ADP + phosphorylated huntingtin
-
-
-
-
?
ATP + huntingtin
ADP + phosphorylated huntingtin
-
huntingtin is phosphorylated by Cdk5 at Ser1181 and Ser1201
-
-
?
ATP + huntingtin
ADP + phosphorylated huntingtin
-
huntingtin is phosphorylated by Cdk5 at Ser1181 and Ser1201
-
-
?
ATP + MAP1B
ADP + phosphorylated MAP1B
-
reaction in growth cones is important for stability of microtubules
-
-
?
ATP + MAP1B
ADP + phosphorylated MAP1B
-
type 1 phosphorylation in the mab1E11 recognition site
-
-
?
ATP + MAP1B
ADP + phosphorylated MAP1B
-
-
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
-
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
-
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
-
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
phosphorylation at Thr286
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
-
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
-
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEP50 protein
ADP + MEP50 phosphoprotein
-
a PRMT5 co-regulatory factor
-
-
?
ATP + MEP50 protein
ADP + MEP50 phosphoprotein
-
a PRMT5 co-regulatory factor, purified recombinant PRMT5/MEP50 produced in Sf9 cells or HeLa cells, phosphorylation of Thr5 and perhaps Ser264 by CDK4
-
-
?
ATP + MEP50 protein
ADP + MEP50 phosphoprotein
-
a PRMT5 co-regulatory factor
-
-
?
ATP + Munc-18
ADP + phosphorylated Munc-18
-
-
-
-
?
ATP + Munc-18
ADP + phosphorylated Munc-18
-
involved in regulation of exocytosis involving SNARE proteins, Munc-18 is required for mediating secretory responsesoverview
-
-
?
ATP + neuregulin receptor ErbB2
ADP + phosphorylated neuregulin receptor ErbB2
-
phosphorylation at Ser1176 by Cdk5
-
-
?
ATP + neuregulin receptor ErbB2
ADP + phosphorylated neuregulin receptor ErbB2
-
phosphorylation at Ser1176 in the sequence RPKTLSPGKN by Cdk5
-
-
?
ATP + neuregulin receptor ErbB3
ADP + phosphorylated neuregulin receptor ErbB3
-
phosphorylation at Thr871 and Ser1120 in the consensus sequence RSRSPR by Cdk5, Cdk5 associates with Erb3 in vivo
-
-
?
ATP + neuregulin receptor ErbB3
ADP + phosphorylated neuregulin receptor ErbB3
-
phosphorylation at Thr871 in the sequence AKTPIKWAL and Ser1120 in the consensus sequence RSRSPR by Cdk5, weak phosphorylation of Ser1204 in the proline-rich sequence RRGSPPRPPR
-
-
?
ATP + neuregulin receptor ErbB3
ADP + phosphorylated neuregulin receptor ErbB3
-
phosphorylation at Thr871 and Ser1120 by Cdk5
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein that correlates neurit outgrowth, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats, hyperactivated Cdk5-p25
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein that correlates neurit outgrowth, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein that correlates neurit outgrowth, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NF-H peptide
ADP + phosphorylated NF-H peptide
-
-
-
-
?
ATP + NF-H peptide
ADP + phosphorylated NF-H peptide
-
i.e. RREAKSPAKAKSPAKE
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, hyperactivated Cdk5-p25
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats
-
-
?
ATP + NR1 receptor
ADP + phosphorylated NR1 receptor
-
-
-
-
?
ATP + NR1 receptor
ADP + phosphorylated NR1 receptor
-
involved in synaptic transmission, overview
-
-
?
ATP + NR2 receptor
ADP + phosphorylated NR2 receptor
-
involved in synaptic transmission, phosphorylation of Ser1232 on the A subunit upregulates NMCAR activity, overview
-
-
?
ATP + NR2 receptor
ADP + phosphorylated NR2 receptor
-
with phosphorylation sites on both, A and B subunits, e.g. Ser1232 on the A subunit
-
-
?
ATP + parkin
ADP + phosphorylated parkin
-
Ser-131 located at the linker region of parkin is the major Cdk5 phosphorylation site, phosphorylation by Cdk5 decreases the auto-ubiquitylation of parkin, parkin S131A mutant has 40% lower phosphorylation levels in vivo than wild-type parkin
-
-
?
ATP + parkin
ADP + phosphorylated parkin
-
Ser-131 located at the linker region of parkin is the major Cdk5 phosphorylation site, phosphorylation by Cdk5 decreases the auto-ubiquitylation of parkin
-
-
?
ATP + parkin
ADP + phosphorylated parkin
-
-
-
?
ATP + parkin
ADP + phosphorylated parkin
parkin has four putative Cdk5 phosphorylation sites according to the motif (S/T)PX(K/R)
-
-
?
ATP + PKTPKKAKKL
ADP + PKpTPKKAKKL
-
-
-
-
?
ATP + PKTPKKAKKL
ADP + PKpTPKKAKKL
GST-tagged recombinant peptide substrate
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
-
hyperphosphorylation by CDK/cyclin
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
-
hyperphosphorylation by CDK/cyclin
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
-
hyperphosphorylation by CDK/cyclin
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
-
hyperphosphorylation by CDK/cyclin
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
-
hyperphosphorylation by CDK/cyclin
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
-
hyperphosphorylation by CDK/cyclin
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
-
cyclin-dependent kinase activity is required for progesterone receptor PR function, the phosphorylation of the receptor protein has little effect, but cyclin A/Cdk2 acts as a progesterone receptor coactivator via stimulation of PR transcription, Cdk2-cyclin A is PR-dependently recruited to the PR promoter binding to cyclin A, mechanism involving SCR-1 and regulation, overview
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
-
Cdk2-cyclin A
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
-
cyclin A2/Cdk2 phosphorylates progesterone receptor in vivo at Ser20 and Ser676, Ser162, Ser190 and Ser400
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
-
cyclin A2/Cdk2 phosphorylates progesterone receptor in vitro at Ser25, Ser162, Ser190, Ser213, Ser400, Thr 430, Ser554 and Ser676
-
-
?
ATP + protein
ADP + phosphoprotein
NIMA is a cell cycle regulated protein kinase required, in addition to p34cdc2/cyclin B, for initiation of mitosis. NIMA accumulates when cells are arrested in G2 and is degraded as cells traverse mitosis. NIMA degradation during mitosis is required for correct mitotic progression in Aspergillus nidulans
-
-
?
ATP + protein
ADP + phosphoprotein
proline-directed kinase
-
-
?
ATP + protein
ADP + phosphoprotein
-
-
-
?
ATP + protein
ADP + phosphoprotein
the enzyme is likely to be involved in regulating the cell cycle and therefore may have a role in oncogenesis
-
-
?
ATP + protein
ADP + phosphoprotein
proline-directed kinase
-
-
?
ATP + protein
ADP + phosphoprotein
serine/threonine-specific protein kinase
-
-
?
ATP + protein
ADP + phosphoprotein
receptor protein tyrosine kinase
-
-
?
ATP + protein
ADP + phosphoprotein
Ser/Thr kinase
-
-
?
ATP + protein
ADP + phosphoprotein
-
-
-
?
ATP + protein
ADP + phosphoprotein
Ser/Thr kinase
-
-
?
ATP + protein tau
ADP + protein tau phosphate
-
-
-
-
?
ATP + protein tau
ADP + protein tau phosphate
-
-
-
-
?
ATP + Rad9 protein
ADP + Rad9 phosphoprotein
-
a DNA damage response mediator
-
-
?
ATP + Rad9 protein
ADP + Rad9 phosphoprotein
-
a DNA damage response mediator, phosphorylaation at Thr125 and Thr143
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
-
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
phosphorylation by CDK4/cyclin D at one site, or by CDK2/cyclin E or A at multiple sites in the cell cycle G1 phase
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, phosphorylation by CDK4/cyclin D
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, phosphorylation by CDK4/cyclin D at one site, or by CDK2/cyclin E or A at multiple sites
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, recombinant GST-tagged substrate, substrate of e.g. of chimeric K-cyclin/cdk6 and K-cyclin-cyclin D2
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
-
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
the phosphorylation site is at Ser795
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin
-
-
?
ATP + retinoblastoma protein
ADP + retinoblastoma phosphoprotein
-
a tumor suppressor protein
-
-
?
ATP + retinoblastoma protein
ADP + retinoblastoma phosphoprotein
-
a tumor suppressor protein, phosphorylated by Cdk5-p25
-
-
?
ATP + retinoblastoma-related protein
ADP + phosphorylated retinoblastoma-related protein
-
i.e. RBR, substrate of Cdk-A/cyclin D2
-
-
?
ATP + retinoblastoma-related protein
ADP + phosphorylated retinoblastoma-related protein
-
i.e. RBR, substrate of Cdk-A/cyclin D2 and of proliferating cell nuclear antigen/cyclin D2
-
-
?
ATP + RhoGEF Tus1p
ADP + phosphorylated RhoGEF Tus1p
-
-
-
-
?
ATP + RhoGEF Tus1p
ADP + phosphorylated RhoGEF Tus1p
-
-
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
-
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
phosphorylate the C-terminal domain of RNA polymerase II
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
-
-
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
-
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
CDK9 phosphorylates the carboxy-terminal domain of the largest subunit (RPB1) of RNA polymerase II
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
-
CDK7 and CDK8 phosphorylate the C-terminal domain of RNA Pol II
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
-
-
-
?
ATP + RNA polymerase II C-terminal domain
ADP + phosphorylated RNA polymerase II C-terminal domain
-
phosphorylation by Cdk7 and Cdk9, phosphorylation at serine residues 2 and 5
-
-
?
ATP + RNA polymerase II C-terminal domain
ADP + phosphorylated RNA polymerase II C-terminal domain
-
reccombinant GST-tagged substrate
-
-
?
ATP + SCR-1
ADP + phosphorylated SCR-1
-
Cdk2-cyclin A, phosphorylation at Lys5 regulates SCR-1 interaction with the progesterone receptor
-
-
?
ATP + SCR-1
ADP + phosphorylated SCR-1
-
Cdk2-cyclin A, phosphorylation at Lys5
-
-
?
ATP + septine 5
ADP + phosphorylated septine 5
-
Ser327 is the major phosphorylation site for Cdk5 in presence of activator p35
-
-
?
ATP + septine 5
ADP + phosphorylated septine 5
-
Ser327 is the major phosphorylation site for Cdk5 in presence of activator p35
-
-
?
ATP + Sic1
ADP + phosphorylated Sic1
-
-
-
-
?
ATP + Sic1
ADP + phosphorylated Sic1
-
Glc8 function is dependent on phosphorylation at Thr-118, which is phosphorylated by Pho85 in conjunction with cyclins Pcl6 and Pcl7, and possibly Pcl8 and Pcl10
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
-
substrate of CDK5
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
-
-
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
-
specific phosphorylation at Ser727 by CDK5-p35, CDK5 is involved in regulation of the signal transducer and transcription activator STAT3 in brain and muscle
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
-
specific phosphorylation at Ser727 by CDK5-p35
-
-
?
ATP + STAU2
ADP + phosphorylated STAU2
STAU2 is hyperphosphorylated during mitosis and that CDK1 participates in the process. Several phosphorylated amino acids residues are localized as clusters in the C-terminal region of STAU2
-
-
?
ATP + STAU2
ADP + phosphorylated STAU2
STAU2 isoforms are phosphorylated on several amino acid residues in the C-terminal half
-
-
?
ATP + steroidogenic factor 1
ADP + phosphorylated steroidogenic factor 1
also known as Ad4BP, systematic name NR5A1, the phosphorylation site is at Ser203
-
-
?
ATP + steroidogenic factor 1
ADP + phosphorylated steroidogenic factor 1
also known as Ad4BP, systematic name NR5A1, the phosphorylation site is at Ser203
-
-
?
ATP + syntaxin-1
ADP + phosphorylated syntaxin-1
-
-
-
-
?
ATP + syntaxin-1
ADP + phosphorylated syntaxin-1
-
-
-
-
?
ATP + T-cell protein tyrosine phosphatase
ADP + phosphorylated T-cell protein tyrosine phosphatase
-
phosphorylation of the two splicing varaints TC45 and TC48 at Ser304 in a cell cycle-dependent manner, optimally in mitosis, overview
-
-
?
ATP + T-cell protein tyrosine phosphatase
ADP + phosphorylated T-cell protein tyrosine phosphatase
-
phosphorylation of the two splicing varaints TC45 and TC48 at Ser304 in the sequence AFDHS(P), no activity with substrate mutant S304A
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
-
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
-
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
hyperactivated Cdk5-p25
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
Cdk5 phosphorylates at S202, S235, and S404, phosphorylation at S235 primes it for phosphorylation of T231 by GSK3beta, phosphorylating tau protein at S404 primes tau protein for a sequential phosphorylation of S400 and S396 by GSK3beta
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
phosphorylation at Ser235 by cdk5 primes phosphorylation at Thr231 by GSK-3alpha/beta. Tau protein isoforms with the two N-terminal inserts s4L and s3L are more favorable substrates than tau protein isoforms without the inserts. Thr231 is phosphorylated ca. 50% more in free tau protein than in microtubule-bound one
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
-
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
cdk5 substrate in brain, Cdk5-p25 or Cdk5-p35
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
hyperactivated Cdk5-p25
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
-
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
cdk5 substrate in brain, Cdk5-p25 or Cdk5-p35
-
-
?
ATP + Tau protein
ADP + Tau phosphoprotein
-
Cdk5-p25 has a stronger Tau-phosphorylating activity than Cdk5-p35 in neurons
-
-
?
ATP + Tau protein
ADP + Tau phosphoprotein
-
Cdk5-p25 or Cdk5-p35 or Cdk5-p39
-
-
?
ATP + Varicella-Zoster virus IE63 protein
ADP + phosphorylated Varicella-Zoster virus IE63 protein
-
phosphorylation at Ser224 by CDK1 in vivo is required for correct localization of the virus protein, e.g. in the host cytoplasm during latency, S224A mutation leads to inhibition of phosphorylation and exclusive localization of IE63 protein in the nucleus
-
-
?
ATP + Varicella-Zoster virus IE63 protein
ADP + phosphorylated Varicella-Zoster virus IE63 protein
-
recombinant wild-type and mutant IE63 proteins expressed in Vero cells, phosphorylation at Ser224 of wild-type and mutants T222E and T222A by CDK1 and CDK5, but not by CDK2, CDK7, and CDK9 in vitro, mutant S224A is no substrate
-
-
?
ATP + VGCC
ADP + phosphorylated NR1 receptor
-
a voltage-dependent calcium channel, phosphorylation within the intracellular loop of the channel inhibiting interaction with SNARE proteins, SNAP-25, and synaptotagmin I required for neurotransmitter release, overview
-
-
?
ATP + VGCC
ADP + phosphorylated NR1 receptor
-
a voltage-dependent calcium channel, phosphorylation within the intracellular loop of the channel
-
-
?
ATP + Wee1A
ADP + phosphorylated Wee1A
-
phosphorylation at S123, S53, and S121 promotes binding of Wee1A by beta-TrCP, the beta-transducin repeat-containing protein, which is the substrate recognition component of the ubiquitin ligase, leading to proteasomal degradation of Wee1A, overview
-
-
?
ATP + Wee1A
ADP + phosphorylated Wee1A
-
phosphorylation at S123, S53, and S121
-
-
?
ATP + [elongation factor 2]
ADP + [elongation factor 2]phosphate
-
the enzyme phosphorylates Ser595. Ser595 phosphorylation varies during the cell cycle and is required for efficient Thr56 phosphorylation (by elongation factor 2 kinase) in vivo
-
-
?
ATP + [elongation factor 2]
ADP + [elongation factor 2]phosphate
-
the enzyme phosphorylates Ser595
-
-
?
ATP + [tau protein]
ADP + O-phospho-[tau-protein]
-
Cdk5-p25 or Cdk5-p35, see also EC 2.7.11.26
-
-
?
ATP + [tau protein]
ADP + O-phospho-[tau-protein]
-
Cdk5-p25 or Cdk5-p35, see also EC 2.7.11.26, phosphorylation at Ser202 and Thr205
-
-
?
ATP + [tau protein]
ADP + [O-phospho-tau protein]
-
substrate of CDK5 in the central nervous system, see also EC 2.7.11.26, tau hyperphosphorylation is involved in neurodegeneration and Alzheimer's disease, tau protein phosphorylation by CDK5 is involved in apoptosis in cortical cells
-
-
?
ATP + [tau protein]
ADP + [O-phospho-tau protein]
-
substrate of CDK5 in the central nervous system, see also EC 2.7.11.26, phosphorylation at the PHF-1 epitope, not the Tau-1 epitope, of tau protein by CDK5-p25
-
-
?
ATP + [tau-protein]
ADP + O-phospho -[tau-protein]
-
cdk5 substrate in brain, cdk5 associated with p39, tau is a microtubule-associated and developmentally regulated protein involved in axonal development in neurons, tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules, reaction of EC 2.7.11.26
-
-
?
ATP + [tau-protein]
ADP + O-phospho -[tau-protein]
-
preferred substrate of cdk5 associated with p39, recombinant bacterially expressed human tau protein as substrate, phosphorylation at Ser202 and Thr205, reaction of EC 2.7.11.26
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
-
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
cdk5 associated with p25, cdk5 substrate in brain
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
cdk5 associated with p25, recombinant bacterially expressed human tau protein as substrate, phosphorylation of the AT8 and AT180 epitopes, and at T231 of the Alzheimer's mitotic epitope TG-3
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
-
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
activity in organisms with mutated APP and tau, not in wild-type, overview
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
hyperphosphorylation of tau by CDK5 is involved in apoptosis and neurodegeneration in Alzheimer's disease, overview
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
phosphorylation of the PHF-1 epitope at Ser396 and Ser404 by CDK5
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
tau is microtubule-associated, phopshorylation at T231 by CDK5 causes its release into the cytoplasm
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
phosphorylation at T231, no activity with tau mutant T231A
-
-
?
N6-PhEt-ATP-gamma-S + pfkB-like carbohydrate kinase family protein
?
-
gene locus At2g31390
-
-
?
N6-PhEt-ATP-gamma-S + pfkB-like carbohydrate kinase family protein
?
-
gene locus At5g51830
-
-
?
additional information
?
-
enzyme may play a role in the regulation of plant growth and development
-
-
?
additional information
?
-
enzyme plays a central role in control of the mitotic cell cycle
-
-
?
additional information
?
-
enzyme plays a central role in control of the mitotic cell cycle
-
-
?
additional information
?
-
-
enzyme plays a central role in control of the mitotic cell cycle
-
-
?
additional information
?
-
key component of the eukaryotic cell cycle, which is required for G1 to S-phase transition and for entry into mitosis
-
-
?
additional information
?
-
-
key component of the eukaryotic cell cycle, which is required for G1 to S-phase transition and for entry into mitosis
-
-
?
additional information
?
-
-
plant-specific cyclin-dependent kinase CDKB1,1 and transcription factor E2Fa-DPa control the balance of mitotically dividing and endoreduplicating cells in Arabidopsis thaliana, CDKB1,1 is required to inhibit the endocycle and promote the ectopic cell divisions triggered by E2Fa-DPa, regulation model
-
-
?
additional information
?
-
-
the enzyme interacts with kinesin-like proteins KCA1 and KCA2 and is required for their activity and protein folding, and is influenced by the phosphorylation status of KCA1 and KCA2, the interaction plays a role in the cell cycle and cell division, overview
-
-
?
additional information
?
-
-
the plant-specific kinase CDKF,1 is involved in activating phosphorylation of CDK-activating kinases in Arabidopsis
-
-
?
additional information
?
-
-
the enzyme interacts with kinesin-like proteins KCA1 and KCA2, which possess N-terminal ATP and microtubule binding sites, as well as potential C-terminal CDK phosphorylation sites at positions 698, 849, and 853 in KCA1, and at positions 827 and 831 in KCA2, overview
-
-
?
additional information
?
-
-
the CDKs PHOA is involved in modulation of differentiation in response to environmental conditions, including limited phosphorous, but does not play an essential role in regulation of phosphorous aquisition
-
-
?
additional information
?
-
enzyme is required for M phase in meiotic and mitotic cell divisions, but not for S phase
-
-
?
additional information
?
-
-
enzyme is required for M phase in meiotic and mitotic cell divisions, but not for S phase
-
-
?
additional information
?
-
can properly regulate the cell cycle
-
-
?
additional information
?
-
-
can properly regulate the cell cycle
-
-
?
additional information
?
-
-
Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins
-
-
?
additional information
?
-
enzyme is involved in Dictyostelium differentiation rather than growth
-
-
?
additional information
?
-
-
enzyme is involved in Dictyostelium differentiation rather than growth
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins
-
-
?
additional information
?
-
-
regulation mechanisms, overview
-
-
?
additional information
?
-
-
poor activity on free amino acids, consensus sequence of cdk2 is S/TP-XR/K
-
-
?
additional information
?
-
-
multisite phosphorylation and network dynamics of cyclin-dependent kinase signaling in the eukaryotic cell cycle, determination of the importance of phosphorylations of regulatory proteins in the cell cycle and biological network, CDK regulation involving positive feedback by Cdc25, Wee1, and CAK, mathematical modeling, overview
-
-
?
additional information
?
-
-
Cdk5 is crucial for stability of axons and growth cones in retina, overview
-
-
?
additional information
?
-
CDKA1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
CDKA1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
-
CDKA1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
CDKB1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
CDKB1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
-
CDKB1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
the gene coding for the enzyme is a candidate for the following disorders: Nance-Horan syndrome, oral-facial-digital syndrome type 1, and nonsyndromic sensorineural deafness
-
-
?
additional information
?
-
CDK4 amplification might contribute to oncogenesis
-
-
?
additional information
?
-
-
CDK4 amplification might contribute to oncogenesis
-
-
?
additional information
?
-
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
-
-
?
additional information
?
-
-
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
-
-
?
additional information
?
-
CDK9 is the catalytic subunit of a general RNA polymerase II elongation factor termed p-TEFb which is targeted by the human immunodeficiency virus Tat protein to activate elongation of the integrated proviral genome
-
-
?
additional information
?
-
CDK9 is the catalytic subunit of a general RNA polymerase II elongation factor termed p-TEFb which is targeted by the human immunodeficiency virus Tat protein to activate elongation of the integrated proviral genome
-
-
?
additional information
?
-
proper regulation of p58 protein kinase is essential for normal cell cycle progression in these cells
-
-
?
additional information
?
-
-
proper regulation of p58 protein kinase is essential for normal cell cycle progression in these cells
-
-
?
additional information
?
-
PISSLRE could be involved in processes distinct from cell proliferation
-
-
?
additional information
?
-
-
PISSLRE could be involved in processes distinct from cell proliferation
-
-
?
additional information
?
-
human K35-cyclin C might be functionally associated with the mammalian transcription apparatus, perhaps involved in relaying growth-regulatory signals
-
-
?
additional information
?
-
-
human K35-cyclin C might be functionally associated with the mammalian transcription apparatus, perhaps involved in relaying growth-regulatory signals
-
-
?
additional information
?
-
enzyme plays an important role in spermatogenesis
-
-
?
additional information
?
-
TFIIH is a multisubunit complex, containing ATPase, helicases, and kinase subunit of TFIIH. In mitosis the CDK7 subunit of TFIIH and the largest subunit of RNAPII become hyperphosphorylated. MPF-induced phosphorylation of CDK7 results in inhibition of the TFIIH-associated kinase and transcription activities
-
-
?
additional information
?
-
CDK4 gene is a melanoma-predisposing gene
-
-
?
additional information
?
-
cdk7 is a subunit of the transcription/DNA repair factor TFIIH, cdk7 may phosphorylate the carboxy-terminal domain of RNA pol II in the absence of promoter opening
-
-
?
additional information
?
-
-
abnormal phosphorylation of tau in dividing cells leads to its accumulation in the cytosol as microtubule-free form, Cdk5 is involved in neurodegenerative mechanisms
-
-
?
additional information
?
-
-
naturally occurring V717I mutation of the amyloid precursor protein APP in a CT100 fragment of organisms with Alzheimer's disease leads to augmented age-dependent tau phosphorylation, followed by increased activation status of mitogen-activated protein kinase family members, e.g. ERK1/2, p38, and c-Jun NH2-terminal kinase, compared to the wild-type organism, naturally occurring V337M mutation of tau protein of patients suffering from Alzheimer's disease leads to age-dependent memory deficits
-
-
?
additional information
?
-
-
cdk5 catalyzes tau phosphorylation in brain, but cyclin-dependent phosphorylation of other proteins, EC 2.7.11.22, in different tissues
-
-
?
additional information
?
-
-
CDK-cyclins and CDK inhibitory proteins are involved in the cell cycle regulation and of vascular cell proliferation and migration, as well as in the control of neointimal thickening, modeling, overview
-
-
?
additional information
?
-
-
Cdk1/cyclin B is induced in cells with dysregulated cell cycle, e.g. after infection with the human cytomegalovirus, regulation mechanisms, overview
-
-
?
additional information
?
-
CDK11p110 is involved in transcription and RNA processing
-
-
?
additional information
?
-
-
CDK11p58 interacts with the histone acetyltransferase HBO1 in vitro and in vivo, CDK11p58 acts as a regulator of HBO1 activity in eukaryotic transcription
-
-
?
additional information
?
-
-
CDK4 governs cell cycle progression through the G1 phase, CDK2 is involved in all cell cycle phases, overview
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 regulates endocytosis through association with amphiphysin and dynamin, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
CDK6/cyclin D1 enhances the transition of cells through the G1 phase of the cell cycle, CDK6 without bound cyclin D1 associates with the androgen receptor AR and enhances, independently of its kinase activity, its transcriptional activity in presence of dihydrotestosterone in prostate cancer cells, this stimulation is highly exaggerated with AR mutant T877A found in prostate cancer, thus CDK6 is probably important for prostate cancer development, CDK6 is no essential for stimulation of AR, overview
-
-
?
additional information
?
-
-
Cdks are cell cycle regulating enzymes, the spindle checkpoint requires cyclin-dependent kinase activity, regulation overview
-
-
?
additional information
?
-
-
CDKs are cell cycle-related enzymes, CDK5 activity increases 1.6fold within 5 weeks during neuronal cell differentiation induced by retinoic acid, while the activity of CDK1 and CDK2 decreases by 14.4fold, overview
-
-
?
additional information
?
-
-
constitutitve activation of CDK2-cyclin E leads to G1/S deregulation and tumor progression
-
-
?
additional information
?
-
-
herpes simplex virus type 1 ICP0 directs the degradation of cellular proteins associated with nuclear structures called ND10 by transactivation of promoters and gene expression involving cdks, overview, virus replication, of HSV-1, HSV-2, HMCV, and varicella-zoster virus, is inhibited by inhibition of cdks by inhibiting specific steps or activities of viral regulatory proteins, thus cdks have broad and pleiotropic effects on virus replication, overview
-
-
?
additional information
?
-
-
p34SEI-1 is involved in regulation of CDK4-cyclin D2 activity
-
-
?
additional information
?
-
-
the CDKs are involved in regulation of cell cycle and neuronal differentiation
-
-
?
additional information
?
-
-
the CDKs play a central role in cell cycle control, apoptosis, transcription, and neuronal functions
-
-
?
additional information
?
-
-
the polo-kinase 1, EC 2.7.11.21, also phosphorylates Wee1A at S53 and S123, casein kinase II, EC 2.7.11.1, also phosphorylates Wee1A at S121
-
-
?
additional information
?
-
-
there is cross-talk between the NF-kappaB/IkappaBalpha pathway and the p16/CDK4/Rb pathway in cells with IkappaBalpha being capable to substitute for the inhibitory function of p16 on CDK4, regulation
-
-
?
additional information
?
-
-
viral infection causes dysregulation of multiple human host cell cycle-regulatory proteins, cdks are involved in viral replication, overview, cdk is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production
-
-
?
additional information
?
-
-
viral K-cyclin has a much longer half-life compared to cellular cyclins because it lacks the PEST degradation sequence, the viral K-cyclin can substitute the cellular cyclins in binding to the cellular CDKs, which is important for the virus development, chimeric K-cyclin-cdks are also translocated to the nucleus, chimeric K-cyclin/cdk6 kinase is constitutively active in BC cells, chimeric K-cyclin-cyclin D2 can act as a CDK
-
-
?
additional information
?
-
CDK11p110 interacts with Hsp90, and the serine/threonine kinase CK2, the C-terminal domain of the largest subunit of RNA polymerase II is no substrate of CDK11p110, but of CK2
-
-
?
additional information
?
-
-
CDK11p58 interacts with the histone acetyltransferase HBO1 in vitro and in vivo
-
-
?
additional information
?
-
-
Cdk5 associates with amphiphysin and dynamin
-
-
?
additional information
?
-
-
determination and analysis of CDK2 consensus sequence X-S/T(P)-P-X-K/R, modeling of substrate binding, structure analysis
-
-
?
additional information
?
-
-
enzyme cdk2, cdk4, and especially cdk6 interact with the KSHV viral K-cyclin, a homologue of cellular cyclin D, in BC3 cells, K-cyclin also interacts with p21Cip1 and p27Kip1 in the cells, chimeric K-cyclin/cdk6 kinase is constitutively active, chimeric K-cyclin-cyclin D2 can act as a CDK
-
-
?
additional information
?
-
-
autophosphorylation activity
-
-
?
additional information
?
-
-
kinase properties of Cdk5 are similar to those of Cdk1-cyclin B. Tau and Dab1 are phosphorylated by Cdk5-p39 and Cdk5-p35 at the same sites
-
-
?
additional information
?
-
-
the enzyme depends on basic residues for substrate recognition, autoregulation by a pseudosubstrate mechanism, overview
-
-
?
additional information
?
-
control point in cell cycle
-
-
?
additional information
?
-
-
control point in cell cycle
-
-
?
additional information
?
-
the cdc2 protein kinase plays a role in transcriptional regulation
-
-
?
additional information
?
-
potential function in sensory cells
-
-
?
additional information
?
-
enzyme may have a critical function during normal embryonic development and continues to be expressed in differentiated adult tissues
-
-
?
additional information
?
-
-
enzyme may have a critical function during normal embryonic development and continues to be expressed in differentiated adult tissues
-
-
?
additional information
?
-
enzyme is involved in signal transduction process of pattern formation in the hindbrain
-
-
?
additional information
?
-
enzyme is involved in signal transduction process of pattern formation in the hindbrain
-
-
?
additional information
?
-
-
enzyme is involved in signal transduction process of pattern formation in the hindbrain
-
-
?
additional information
?
-
-
naturally occurring V717I mutation of the amyloid precursor protein APP in a CT100 fragment of mutants leads to augmented age-dependent tau phosphorylation, followed by increased activation status of mitogen-activated protein kinase family members, e.g. ERK1/2, p38, and c-Jun NH2-terminal kinase, compared to the wild-type organism, naturally occurring V337M mutation of tau protein of mutants leads to age-dependent memory deficits
-
-
?
additional information
?
-
-
cdk5 catalyzes tau phosphorylation in brain, but cyclin-dependent phosphorylation of other proteins, EC 2.7.11.22, in different tissues
-
-
?
additional information
?
-
-
CDK-cyclins and CDK inhibitory proteins are involved in the cell cycle regulation and of vascular cell proliferation and migration, as well as in the control of neointimal thickening, modeling, overview
-
-
?
additional information
?
-
-
Cdk5 regulates Akt activation and cell survival through the neuregulin-mediated PI 3-kinase signaling pathway, null mutants show lower phosphatidylinositol 3-kinase activity, Cdk5-p35 mediates neuroprotection
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, and is critical for neuronal survival, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
the CDKs are involved in regulation of cell cycle and neuronal differentiation, cleavage of p35 to p25 occurs in neurons undergoing induced cell death and in brains exposed to ischaemia
-
-
?
additional information
?
-
no detectable kinase activity towards CDKs, the Pol II carboxyl-terminal domain (CTD), histone H1 or myelin basic protein
-
-
?
additional information
?
-
-
Cdk5 is a modulator of spine morphogenesis
-
-
?
additional information
?
-
-
the CDK2-cyclin E complex is a inducer of S-phase entry and key factor for the initiation of centrosome duplication, that CDK4/6-cyclin D are the proteins that compensates for the loss of CDK2 in the initiation of centrosome duplication
-
-
?
additional information
?
-
-
phosphorylation of T161 in plant CDKA is required for activation of its associated kinase
-
-
?
additional information
?
-
-
CDK is involved in control of cell differentiation and organogenesis
-
-
?
additional information
?
-
-
CDKB and CDKA are regulated through phosphorylation and cyclins A and B during the cll cycle, regulation overview
-
-
?
additional information
?
-
-
CDKB ia a B1-type CDK with A-type features
-
-
?
additional information
?
-
-
the enzyme interacts specifically with Cdc kinase subunit 1
-
-
?
additional information
?
-
-
autophosphorylation of Pfmrk, can not phosphorylate PfPK5
-
-
?
additional information
?
-
the enzyme is a component of maturation-promoting factor
-
-
?
additional information
?
-
-
the enzyme is a component of maturation-promoting factor
-
-
?
additional information
?
-
enzyme is required for mitosis
-
-
?
additional information
?
-
enzyme plays an important role in spermatogenesis
-
-
?
additional information
?
-
Cdk2 protein might be required for entry into the S phase of the cell cycle in FRTL-Tc cells
-
-
?
additional information
?
-
-
CDK5-dependent clustering of endoplasmic reticulum ER and mitochondria during ceramide-mediated neuronal death: neurotoxic calcium transfer from ER to mitochondria is regulated by cyclin-dependent kinase 5-dependent phosphorylation of tau, inhibition of the process leads to cell death
-
-
?
additional information
?
-
-
CDK-cyclins and CDK inhibitory proteins are involved in the cell cycle regulation and of vascular cell proliferation and migration, as well as in the control of neointimal thickening, modeling, overview
-
-
?
additional information
?
-
-
Cdk5 regulates Akt activation and cell survival through the neuregulin-mediated PI 3-kinase signaling pathway, null mutants show lower phosphatidylinositol 3-kinase activity, Cdk5-p35 mediates neuroprotection
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
Cdk5-p35 is negatively regulated by interaction with membranes in brain and liver, mechanism
-
-
?
additional information
?
-
-
cyclin-dependent kinase activity is required for apoptotic death involving the retinoblastoma protein but not inclusion formation in cortical neurons after proteasomal inhibition, Cdk2, Cdk4, and Cdk6 promote the apoptosis induced by lactacystin and other proteasome inhibitors, expression of a defective retinoblastoma protein is neuroprotective
-
-
?
additional information
?
-
-
the CDKs are involved in regulation of cell cycle and neuronal differentiation, cleavage of p35 to p25 occurs in neurons undergoing induced cell death and in brains exposed to ischaemia
-
-
?
additional information
?
-
-
the phosphatidylinositol-linked dopamine receptor is involved in regulation of cdk5 enzyme activity in the brain
-
-
?
additional information
?
-
-
CDK5 induces caspase-independent mitochondrial fission
-
-
?
additional information
?
-
enzyme is required for initiation of meiosis and sporulation
-
-
?
additional information
?
-
negative regulatory factors of the PHO system
-
-
?
additional information
?
-
-
negative regulatory factors of the PHO system
-
-
?
additional information
?
-
Kin28 may be a cyclin dependent kinase which is required for cell proliferation
-
-
?
additional information
?
-
enzyme is required for induction of meiosis
-
-
?
additional information
?
-
-
determination of cyclin specificity of Cdk1 during cell cycle using mutant Cdk1-as1 with an enlarged ATP binding site, overview
-
-
?
additional information
?
-
-
determination of cyclin specificity of Cdk1 with different enzyme substrates using mutant Cdk1-as1 with an enlarged ATP binding site, overview
-
-
?
additional information
?
-
-
Cdk activity is required to fire origins of DNA replication and to prevent 'licensing' (establishing the competence) of additional origins after replication initiation
-
-
?
additional information
?
-
-
once-per-cell-cycle replication is enforced by cyclin-Cdk-dependent phosphorylation of the prereplicative complex components Mcm2-7, Cdc6, and Orc1-6
-
-
?
additional information
?
-
-
Cdk1 controls timing of vacuole movement and regulates vacuole inheritance
-
-
?
additional information
?
-
-
Pho85 is a proline-directed kinase that preferentially phosphorylates the consensus sequence S/T-P-X-I/L. Cln3 contains two of these sites (Ser449 and Thr520) located precisely at the ends of the PEST region. Cln3 is an in vitro substrate of Pho85, and both proteins interact in vivo, Cln3 is a molecular target of the Pho85 kinase
-
-
?
additional information
?
-
the enzyme requires no phosphorylation for kinase activity
-
-
?
additional information
?
-
-
the enzyme requires no phosphorylation for kinase activity
-
-
?
additional information
?
-
-
Pho85 is a proline-directed kinase that preferentially phosphorylates the consensus sequence S/T-P-X-I/L. Cln3 contains two of these sites (Ser449 and Thr520) located precisely at the ends of the PEST region. Cln3 is an in vitro substrate of Pho85, and both proteins interact in vivo, Cln3 is a molecular target of the Pho85 kinase
-
-
?
additional information
?
-
enzyme is required for both the G1-S and G2-M transitions during mitotic growth, and also for the second meiotic nuclear division
-
-
?
additional information
?
-
-
enzyme is required for both the G1-S and G2-M transitions during mitotic growth, and also for the second meiotic nuclear division
-
-
?
additional information
?
-
the enzyme is required during both G1 and G2 phases of the cell division cycle
-
-
?
additional information
?
-
-
the enzyme is required during both G1 and G2 phases of the cell division cycle
-
-
?
additional information
?
-
csk1 may encode a protein kinase physically associated with mcs2 or alternatively may function as an upstream activator of the mcs2-associated kinase
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
cdc2-related kinase 12 autophosphorylates in vivo
-
-
?
additional information
?
-
enzyme may be involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
enzyme may be involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
enzyme may be involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
enzyme is involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
enzyme is involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
enzyme is involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
-
cdc2-related kinase 12 autophosphorylates in vivo
-
-
?
additional information
?
-
enzyme is required both for entry into S phase and mitosis
-
-
?
additional information
?
-
enzyme is involved in negative regulation of meiotic maturation of Xenopus oocytes
-
-
?
additional information
?
-
-
Cdks are cell cycle regulating enzymes, Cdk1 phosphorylates the anaphase-promoting complex-cyclosome during mitosis, which is a prerequisite for its activity but reduces the anaphase-promoting complex-cyclosome interaction with Cdc20 involving Mad2, the spindle checkpoint requires cyclin-dependent kinase activity, inhibition of Cdk overrides checkpoint-dependent arrest in eggs increasing the interaction of the anaphase-promoting complex-cyclosome with Cdc20, regulation overview
-
-
?
additional information
?
-
-
identification 35 substrates from screening for cyclin B/CDK1, and investigation of the differential specificity of cyclin B/CDK1 versus cyclin A/CDK1 and cyclin A/CDK2. About half the substrates are equally well phosphorylated regardless of the cyclin or the CDK, computational analysis, overview
-
-
?
additional information
?
-
-
Cdk-A/cyclin D2 is involved in DNA replication progress and cell proliferation
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ATP + 1-(beta-D-ribofuranosyl)-nicotinamide
ADP + beta-nicotinamide D-ribonucleotide
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
ATP + a protein
ADP + phosphorylated protein
ATP + axonal cytoskeleton protein
ADP + phosphorylated axonal cytoskeleton protein
-
regulated by integrin alpha1beta1
-
-
?
ATP + bloom syndrome helicase
ADP + phosphorylated bloom syndrome helicase
-
-
-
-
?
ATP + BRCA2
ADP + phosphorylated BRCA2
-
phosphorylates at Ser3291, phosphorylation reaches maximal levels in G2/M
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
ATP + Cdc20
ADP + phosphorylated Cdc20
ATP + CDK1
ADP + phosphorylated CDK1
-
CDK7 phosphorylates the activation segment or T-loop of CDK1
-
-
?
ATP + Cdk1
ADP + phosphorylated Cdk2
-
Cdk7
-
-
?
ATP + cdk2
ADP + phosphorylated cdk2
-
CDK7 phosphorylates the activation segment or T-loop of CDK2
-
-
?
ATP + CDK9
ADP + phosphorylated CDK9
-
-
-
?
ATP + Cprk
ADP + phosphorylated Cprk
-
i.e. Cdk5/p35-regulated kinase
-
-
?
ATP + cyclin-dependent kinase
ADP + phosphorylated cyclin-dependent kinase
-
-
-
?
ATP + Dab1 protein
ADP + Dab1 phosphoprotein
-
-
-
-
?
ATP + dephosphin
ADP + phosphorylated dephosphin
-
Cdk5 regulates endocytosis involving dephosphin activity, overview
-
-
?
ATP + dopamine
ADP + phosphorylated dopamine
-
phosphorylation by cdk5
-
-
?
ATP + dopamine and cAMP-regulated phosphoprotein
ADP + phosphorylated dopamine and cAMP-regulated phosphoprotein
-
i.e. DARPP-32, phosphorylation by cdk5 at Thr75 and Thr34
-
-
?
ATP + early mitotic inhibitor 1 protein
ADP + early mitotic inhibitor 1 phosphoprotein
-
i.e. Emi1, is phosphorylated by CDKs in mitotic but not S-phase cell extracts
-
-
?
ATP + ErbB2
ADP + phosphorylated ErbB2
ATP + ErbB3
ADP + phosphorylated ErbB3
ATP + eukaryotic elongation factor 2
ADP + phosphorylated eukaryotic elongation factor 2
-
phosphorylation on Ser595 by Cdk2
-
-
?
ATP + Fkh2p
ADP + phosphorylated Fkh2p
-
phosphorylation of forkhead transcription factor Fkh2p is part of regulation of cell cycle-specific gene expression, e.g. of the CLB2 cluster, Fkh2p phosphorylation by Cdc28p is regulated by complex formation with Mcm1p and Ndd1p, and phosphorylation, overview
-
-
?
ATP + Gcn4 protein
ADP + phosphorylated Gcn4 protein
-
-
-
?
ATP + Glc8 protein
ADP + phosphorylated Glc8 protein
-
-
-
?
ATP + Gsy2 protein
ADP + phosphorylated Gsy2 protein
-
-
-
?
ATP + histone H1
ADP + phosphorylated histone H1
-
substrate of Cdk-A/cyclin D2
-
-
?
ATP + histone H1
ADP + phosphorylated steroid histone H1
-
-
-
-
?
ATP + MAP1B
ADP + phosphorylated MAP1B
-
reaction in growth cones is important for stability of microtubules
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
ATP + MEP50 protein
ADP + MEP50 phosphoprotein
ATP + Munc-18
ADP + phosphorylated Munc-18
-
involved in regulation of exocytosis involving SNARE proteins, Munc-18 is required for mediating secretory responsesoverview
-
-
?
ATP + neuregulin receptor ErbB2
ADP + phosphorylated neuregulin receptor ErbB2
-
phosphorylation at Ser1176 by Cdk5
-
-
?
ATP + neuregulin receptor ErbB3
ADP + phosphorylated neuregulin receptor ErbB3
ATP + NF-H
ADP + phosphorylated NF-H
ATP + NF-M
ADP + phosphorylated NF-M
ATP + NR1 receptor
ADP + phosphorylated NR1 receptor
-
involved in synaptic transmission, overview
-
-
?
ATP + NR2 receptor
ADP + phosphorylated NR2 receptor
-
involved in synaptic transmission, phosphorylation of Ser1232 on the A subunit upregulates NMCAR activity, overview
-
-
?
ATP + p35 protein
ADP + p35 phosphoprotein
-
a nuclear transcription factor, Cdk5-p25 phosphorylates p53 on Ser15, Ser33, and Ser44
-
-
?
ATP + parkin
ADP + phosphorylated parkin
-
Ser-131 located at the linker region of parkin is the major Cdk5 phosphorylation site, phosphorylation by Cdk5 decreases the auto-ubiquitylation of parkin, parkin S131A mutant has 40% lower phosphorylation levels in vivo than wild-type parkin
-
-
?
ATP + Pho4 protein
ADP + phosphorylated Pho4 protein
-
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
ATP + polymerase II C-terminal domain
ADP + phosphorylated polymerase II C-terminal domain
-
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
ATP + protein
ADP + phosphoprotein
NIMA is a cell cycle regulated protein kinase required, in addition to p34cdc2/cyclin B, for initiation of mitosis. NIMA accumulates when cells are arrested in G2 and is degraded as cells traverse mitosis. NIMA degradation during mitosis is required for correct mitotic progression in Aspergillus nidulans
-
-
?
ATP + Rad9 protein
ADP + Rad9 phosphoprotein
-
a DNA damage response mediator
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
ATP + retinoblastoma protein
ADP + retinoblastoma phosphoprotein
-
a tumor suppressor protein
-
-
?
ATP + retinoblastoma-related protein
ADP + phosphorylated retinoblastoma-related protein
-
i.e. RBR, substrate of Cdk-A/cyclin D2
-
-
?
ATP + Rga2 protein
ADP + phosphorylated Rga2 protein
-
-
-
?
ATP + Rim 15 protein
ADP + phosphorylated Rim15 protein
-
-
-
?
ATP + RNA polymerase II
ADP + phosphorylated RNA polymerase II
-
CDK7 and CDK8 phosphorylate the C-terminal domain of RNA Pol II
-
-
?
ATP + RNA polymerase II C-terminal domain
ADP + phosphorylated RNA polymerase II C-terminal domain
-
phosphorylation by Cdk7 and Cdk9, phosphorylation at serine residues 2 and 5
-
-
?
ATP + RNA polymerase II C-terminal domain protein
ADP + RNA polymerase II C-terminal domain phosphoprotein
-
-
-
-
?
ATP + Rvs167 protein
ADP + phosphorylated Rvs167 protein
-
-
-
?
ATP + SCR-1
ADP + phosphorylated SCR-1
-
Cdk2-cyclin A, phosphorylation at Lys5 regulates SCR-1 interaction with the progesterone receptor
-
-
?
ATP + Sic1 protein
ADP + phosphorylated Sic1 protein
-
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
ATP + STAT3 protein
ADP + STAT3 phosphoprotein
-
Cdk5 phosphorylates at Ser727
-
-
?
ATP + STAU2
ADP + phosphorylated STAU2
STAU2 is hyperphosphorylated during mitosis and that CDK1 participates in the process. Several phosphorylated amino acids residues are localized as clusters in the C-terminal region of STAU2
-
-
?
ATP + T-cell protein tyrosine phosphatase
ADP + phosphorylated T-cell protein tyrosine phosphatase
-
phosphorylation of the two splicing varaints TC45 and TC48 at Ser304 in a cell cycle-dependent manner, optimally in mitosis, overview
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
ATP + Tau protein
ADP + Tau phosphoprotein
-
Cdk5-p25 has a stronger Tau-phosphorylating activity than Cdk5-p35 in neurons
-
-
?
ATP + Varicella-Zoster virus IE63 protein
ADP + phosphorylated Varicella-Zoster virus IE63 protein
-
phosphorylation at Ser224 by CDK1 in vivo is required for correct localization of the virus protein, e.g. in the host cytoplasm during latency, S224A mutation leads to inhibition of phosphorylation and exclusive localization of IE63 protein in the nucleus
-
-
?
ATP + VGCC
ADP + phosphorylated NR1 receptor
-
a voltage-dependent calcium channel, phosphorylation within the intracellular loop of the channel inhibiting interaction with SNARE proteins, SNAP-25, and synaptotagmin I required for neurotransmitter release, overview
-
-
?
ATP + Wee1A
ADP + phosphorylated Wee1A
-
phosphorylation at S123, S53, and S121 promotes binding of Wee1A by beta-TrCP, the beta-transducin repeat-containing protein, which is the substrate recognition component of the ubiquitin ligase, leading to proteasomal degradation of Wee1A, overview
-
-
?
ATP + Whi5 G1 protein
ADP + phosphorylated Whi5 G1 protein
-
-
-
?
ATP + [elongation factor 2]
ADP + [elongation factor 2]phosphate
-
the enzyme phosphorylates Ser595. Ser595 phosphorylation varies during the cell cycle and is required for efficient Thr56 phosphorylation (by elongation factor 2 kinase) in vivo
-
-
?
ATP + [tau protein]
ADP + [O-phospho-tau protein]
-
substrate of CDK5 in the central nervous system, see also EC 2.7.11.26, tau hyperphosphorylation is involved in neurodegeneration and Alzheimer's disease, tau protein phosphorylation by CDK5 is involved in apoptosis in cortical cells
-
-
?
ATP + [tau-protein]
ADP + O-phospho -[tau-protein]
-
cdk5 substrate in brain, cdk5 associated with p39, tau is a microtubule-associated and developmentally regulated protein involved in axonal development in neurons, tau phosphorylation by cyclin-dependent kinase 5/p39 during brain development reduces its affinity for microtubules, reaction of EC 2.7.11.26
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
additional information
?
-
ATP + a protein
ADP + a phosphoprotein
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
-
-
-
-
?
ATP + a protein
ADP + a phosphoprotein
-
-
-
-
?
ATP + a protein
ADP + phosphorylated protein
-
-
-
-
?
ATP + a protein
ADP + phosphorylated protein
-
-
-
-
?
ATP + a protein
ADP + phosphorylated protein
-
-
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + c-Jun N-terminal kinase 3
ADP + phosphorylated c-Jun N-terminal kinase 3
-
i.e. JNK3, phosphorylation inhibits JNK3 and leads to reduced phosphorylation of c-jun and to reduced apoptosis
-
-
?
ATP + Cdc20
ADP + phosphorylated Cdc20
-
Cdk phosphorylation affects interaction of Cdc20 with Mad2 and the anaphase-promoting complex-cyclosome in HeLa cells
-
-
?
ATP + Cdc20
ADP + phosphorylated Cdc20
-
substrate of Cdk1, rather than of Cdk2
-
-
?
ATP + ErbB2
ADP + phosphorylated ErbB2
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + ErbB2
ADP + phosphorylated ErbB2
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + ErbB3
ADP + phosphorylated ErbB3
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + ErbB3
ADP + phosphorylated ErbB3
-
phosphorylation of the neuregulin receptor by Cdk5 is involved in regulation of neuregulin
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEK1
ADP + phosphorylated MEK1
-
Cdk5 regulates the ERK1/2 pathway through phosphorylation of MEK1, overview
-
-
?
ATP + MEP50 protein
ADP + MEP50 phosphoprotein
-
a PRMT5 co-regulatory factor
-
-
?
ATP + MEP50 protein
ADP + MEP50 phosphoprotein
-
a PRMT5 co-regulatory factor
-
-
?
ATP + neuregulin receptor ErbB3
ADP + phosphorylated neuregulin receptor ErbB3
-
phosphorylation at Thr871 and Ser1120 in the consensus sequence RSRSPR by Cdk5, Cdk5 associates with Erb3 in vivo
-
-
?
ATP + neuregulin receptor ErbB3
ADP + phosphorylated neuregulin receptor ErbB3
-
phosphorylation at Thr871 and Ser1120 by Cdk5
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein that correlates neurit outgrowth, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein that correlates neurit outgrowth, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-H
ADP + phosphorylated NF-H
-
neurofilament protein that correlates neurit outgrowth, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + NF-M
ADP + phosphorylated NF-M
-
neurofilament protein, phosphorylation at the KSP repeats, regulated by the myelin-associate glycoprotein
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p107
ADP + phosphorylated pocket protein 107
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + pocket protein p130
ADP + phosphorylated pocket protein 130
-
hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
-
cyclin-dependent kinase activity is required for progesterone receptor PR function, the phosphorylation of the receptor protein has little effect, but cyclin A/Cdk2 acts as a progesterone receptor coactivator via stimulation of PR transcription, Cdk2-cyclin A is PR-dependently recruited to the PR promoter binding to cyclin A, mechanism involving SCR-1 and regulation, overview
-
-
?
ATP + progesterone receptor
ADP + phosphorylated progesterone receptor
-
cyclin A2/Cdk2 phosphorylates progesterone receptor in vivo at Ser20 and Ser676, Ser162, Ser190 and Ser400
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
phosphorylation by CDK4/cyclin D at one site, or by CDK2/cyclin E or A at multiple sites in the cell cycle G1 phase
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein
-
-
?
ATP + retinoblastoma protein
ADP + phosphorylated retinoblastoma protein
-
i.e. Rb protein, hyperphosphorylation by CDK/cyclin contributes to the transactivation of genes with functional E2F-binding sites, including growth and cell-cycle regulators, i.e. c-myc, Rb protein, cdc2, cyclin E, and cyclin A, and genes encoding proteins required for nucleotide and DNA biosynthesis
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
-
substrate of CDK5
-
-
?
ATP + STAT3
ADP + phosphorylated STAT3
-
specific phosphorylation at Ser727 by CDK5-p35, CDK5 is involved in regulation of the signal transducer and transcription activator STAT3 in brain and muscle
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
hyperactivated Cdk5-p25
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
Cdk5 phosphorylates at S202, S235, and S404, phosphorylation at S235 primes it for phosphorylation of T231 by GSK3beta, phosphorylating tau protein at S404 primes tau protein for a sequential phosphorylation of S400 and S396 by GSK3beta
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
cdk5 substrate in brain, Cdk5-p25 or Cdk5-p35
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
hyperactivated Cdk5-p25
-
-
?
ATP + tau protein
ADP + phosphorylated tau protein
-
cdk5 substrate in brain, Cdk5-p25 or Cdk5-p35
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
-
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
cdk5 associated with p25, cdk5 substrate in brain
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
activity in organisms with mutated APP and tau, not in wild-type, overview
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
hyperphosphorylation of tau by CDK5 is involved in apoptosis and neurodegeneration in Alzheimer's disease, overview
-
-
?
ATP + [tau-protein]
ADP + O-phospho-[tau-protein]
-
tau is microtubule-associated, phopshorylation at T231 by CDK5 causes its release into the cytoplasm
-
-
?
additional information
?
-
enzyme may play a role in the regulation of plant growth and development
-
-
?
additional information
?
-
enzyme plays a central role in control of the mitotic cell cycle
-
-
?
additional information
?
-
enzyme plays a central role in control of the mitotic cell cycle
-
-
?
additional information
?
-
-
enzyme plays a central role in control of the mitotic cell cycle
-
-
?
additional information
?
-
key component of the eukaryotic cell cycle, which is required for G1 to S-phase transition and for entry into mitosis
-
-
?
additional information
?
-
-
key component of the eukaryotic cell cycle, which is required for G1 to S-phase transition and for entry into mitosis
-
-
?
additional information
?
-
-
plant-specific cyclin-dependent kinase CDKB1,1 and transcription factor E2Fa-DPa control the balance of mitotically dividing and endoreduplicating cells in Arabidopsis thaliana, CDKB1,1 is required to inhibit the endocycle and promote the ectopic cell divisions triggered by E2Fa-DPa, regulation model
-
-
?
additional information
?
-
-
the enzyme interacts with kinesin-like proteins KCA1 and KCA2 and is required for their activity and protein folding, and is influenced by the phosphorylation status of KCA1 and KCA2, the interaction plays a role in the cell cycle and cell division, overview
-
-
?
additional information
?
-
-
the plant-specific kinase CDKF,1 is involved in activating phosphorylation of CDK-activating kinases in Arabidopsis
-
-
?
additional information
?
-
-
the CDKs PHOA is involved in modulation of differentiation in response to environmental conditions, including limited phosphorous, but does not play an essential role in regulation of phosphorous aquisition
-
-
?
additional information
?
-
enzyme is required for M phase in meiotic and mitotic cell divisions, but not for S phase
-
-
?
additional information
?
-
-
enzyme is required for M phase in meiotic and mitotic cell divisions, but not for S phase
-
-
?
additional information
?
-
can properly regulate the cell cycle
-
-
?
additional information
?
-
-
can properly regulate the cell cycle
-
-
?
additional information
?
-
-
Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
-
-
?
additional information
?
-
-
-
-
-
?
additional information
?
-
-
Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins
-
-
?
additional information
?
-
enzyme is involved in Dictyostelium differentiation rather than growth
-
-
?
additional information
?
-
-
enzyme is involved in Dictyostelium differentiation rather than growth
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins
-
-
?
additional information
?
-
-
regulation mechanisms, overview
-
-
?
additional information
?
-
-
multisite phosphorylation and network dynamics of cyclin-dependent kinase signaling in the eukaryotic cell cycle, determination of the importance of phosphorylations of regulatory proteins in the cell cycle and biological network, CDK regulation involving positive feedback by Cdc25, Wee1, and CAK, mathematical modeling, overview
-
-
?
additional information
?
-
-
Cdk5 is crucial for stability of axons and growth cones in retina, overview
-
-
?
additional information
?
-
CDKA1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
CDKA1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
-
CDKA1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
CDKB1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
CDKB1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
-
CDKB1 is involved in cell cycle regulation and dormancy
-
-
?
additional information
?
-
the gene coding for the enzyme is a candidate for the following disorders: Nance-Horan syndrome, oral-facial-digital syndrome type 1, and nonsyndromic sensorineural deafness
-
-
?
additional information
?
-
CDK4 amplification might contribute to oncogenesis
-
-
?
additional information
?
-
-
CDK4 amplification might contribute to oncogenesis
-
-
?
additional information
?
-
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
-
-
?
additional information
?
-
-
mutation of CDK4 can create a tumor-specific antigen and can disrupt the cell-cycle regulation exerted by the tumor suppressor p16INK4a
-
-
?
additional information
?
-
CDK9 is the catalytic subunit of a general RNA polymerase II elongation factor termed p-TEFb which is targeted by the human immunodeficiency virus Tat protein to activate elongation of the integrated proviral genome
-
-
?
additional information
?
-
CDK9 is the catalytic subunit of a general RNA polymerase II elongation factor termed p-TEFb which is targeted by the human immunodeficiency virus Tat protein to activate elongation of the integrated proviral genome
-
-
?
additional information
?
-
proper regulation of p58 protein kinase is essential for normal cell cycle progression in these cells
-
-
?
additional information
?
-
-
proper regulation of p58 protein kinase is essential for normal cell cycle progression in these cells
-
-
?
additional information
?
-
PISSLRE could be involved in processes distinct from cell proliferation
-
-
?
additional information
?
-
-
PISSLRE could be involved in processes distinct from cell proliferation
-
-
?
additional information
?
-
human K35-cyclin C might be functionally associated with the mammalian transcription apparatus, perhaps involved in relaying growth-regulatory signals
-
-
?
additional information
?
-
-
human K35-cyclin C might be functionally associated with the mammalian transcription apparatus, perhaps involved in relaying growth-regulatory signals
-
-
?
additional information
?
-
enzyme plays an important role in spermatogenesis
-
-
?
additional information
?
-
TFIIH is a multisubunit complex, containing ATPase, helicases, and kinase subunit of TFIIH. In mitosis the CDK7 subunit of TFIIH and the largest subunit of RNAPII become hyperphosphorylated. MPF-induced phosphorylation of CDK7 results in inhibition of the TFIIH-associated kinase and transcription activities
-
-
?
additional information
?
-
CDK4 gene is a melanoma-predisposing gene
-
-
?
additional information
?
-
cdk7 is a subunit of the transcription/DNA repair factor TFIIH, cdk7 may phosphorylate the carboxy-terminal domain of RNA pol II in the absence of promoter opening
-
-
?
additional information
?
-
-
abnormal phosphorylation of tau in dividing cells leads to its accumulation in the cytosol as microtubule-free form, Cdk5 is involved in neurodegenerative mechanisms
-
-
?
additional information
?
-
-
naturally occurring V717I mutation of the amyloid precursor protein APP in a CT100 fragment of organisms with Alzheimer's disease leads to augmented age-dependent tau phosphorylation, followed by increased activation status of mitogen-activated protein kinase family members, e.g. ERK1/2, p38, and c-Jun NH2-terminal kinase, compared to the wild-type organism, naturally occurring V337M mutation of tau protein of patients suffering from Alzheimer's disease leads to age-dependent memory deficits
-
-
?
additional information
?
-
-
CDK-cyclins and CDK inhibitory proteins are involved in the cell cycle regulation and of vascular cell proliferation and migration, as well as in the control of neointimal thickening, modeling, overview
-
-
?
additional information
?
-
-
Cdk1/cyclin B is induced in cells with dysregulated cell cycle, e.g. after infection with the human cytomegalovirus, regulation mechanisms, overview
-
-
?
additional information
?
-
CDK11p110 is involved in transcription and RNA processing
-
-
?
additional information
?
-
-
CDK11p58 interacts with the histone acetyltransferase HBO1 in vitro and in vivo, CDK11p58 acts as a regulator of HBO1 activity in eukaryotic transcription
-
-
?
additional information
?
-
-
CDK4 governs cell cycle progression through the G1 phase, CDK2 is involved in all cell cycle phases, overview
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 regulates endocytosis through association with amphiphysin and dynamin, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
CDK6/cyclin D1 enhances the transition of cells through the G1 phase of the cell cycle, CDK6 without bound cyclin D1 associates with the androgen receptor AR and enhances, independently of its kinase activity, its transcriptional activity in presence of dihydrotestosterone in prostate cancer cells, this stimulation is highly exaggerated with AR mutant T877A found in prostate cancer, thus CDK6 is probably important for prostate cancer development, CDK6 is no essential for stimulation of AR, overview
-
-
?
additional information
?
-
-
Cdks are cell cycle regulating enzymes, the spindle checkpoint requires cyclin-dependent kinase activity, regulation overview
-
-
?
additional information
?
-
-
CDKs are cell cycle-related enzymes, CDK5 activity increases 1.6fold within 5 weeks during neuronal cell differentiation induced by retinoic acid, while the activity of CDK1 and CDK2 decreases by 14.4fold, overview
-
-
?
additional information
?
-
-
constitutitve activation of CDK2-cyclin E leads to G1/S deregulation and tumor progression
-
-
?
additional information
?
-
-
herpes simplex virus type 1 ICP0 directs the degradation of cellular proteins associated with nuclear structures called ND10 by transactivation of promoters and gene expression involving cdks, overview, virus replication, of HSV-1, HSV-2, HMCV, and varicella-zoster virus, is inhibited by inhibition of cdks by inhibiting specific steps or activities of viral regulatory proteins, thus cdks have broad and pleiotropic effects on virus replication, overview
-
-
?
additional information
?
-
-
p34SEI-1 is involved in regulation of CDK4-cyclin D2 activity
-
-
?
additional information
?
-
-
the CDKs are involved in regulation of cell cycle and neuronal differentiation
-
-
?
additional information
?
-
-
the CDKs play a central role in cell cycle control, apoptosis, transcription, and neuronal functions
-
-
?
additional information
?
-
-
the polo-kinase 1, EC 2.7.11.21, also phosphorylates Wee1A at S53 and S123, casein kinase II, EC 2.7.11.1, also phosphorylates Wee1A at S121
-
-
?
additional information
?
-
-
there is cross-talk between the NF-kappaB/IkappaBalpha pathway and the p16/CDK4/Rb pathway in cells with IkappaBalpha being capable to substitute for the inhibitory function of p16 on CDK4, regulation
-
-
?
additional information
?
-
-
viral infection causes dysregulation of multiple human host cell cycle-regulatory proteins, cdks are involved in viral replication, overview, cdk is required at early times for accurate processing and accumulation of the human cytomegalovirus UL122-123 and UL37 immediate-early transcripts and at later times for virus production
-
-
?
additional information
?
-
-
viral K-cyclin has a much longer half-life compared to cellular cyclins because it lacks the PEST degradation sequence, the viral K-cyclin can substitute the cellular cyclins in binding to the cellular CDKs, which is important for the virus development, chimeric K-cyclin-cdks are also translocated to the nucleus, chimeric K-cyclin/cdk6 kinase is constitutively active in BC cells, chimeric K-cyclin-cyclin D2 can act as a CDK
-
-
?
additional information
?
-
control point in cell cycle
-
-
?
additional information
?
-
-
control point in cell cycle
-
-
?
additional information
?
-
the cdc2 protein kinase plays a role in transcriptional regulation
-
-
?
additional information
?
-
potential function in sensory cells
-
-
?
additional information
?
-
enzyme may have a critical function during normal embryonic development and continues to be expressed in differentiated adult tissues
-
-
?
additional information
?
-
-
enzyme may have a critical function during normal embryonic development and continues to be expressed in differentiated adult tissues
-
-
?
additional information
?
-
enzyme is involved in signal transduction process of pattern formation in the hindbrain
-
-
?
additional information
?
-
enzyme is involved in signal transduction process of pattern formation in the hindbrain
-
-
?
additional information
?
-
-
enzyme is involved in signal transduction process of pattern formation in the hindbrain
-
-
?
additional information
?
-
-
naturally occurring V717I mutation of the amyloid precursor protein APP in a CT100 fragment of mutants leads to augmented age-dependent tau phosphorylation, followed by increased activation status of mitogen-activated protein kinase family members, e.g. ERK1/2, p38, and c-Jun NH2-terminal kinase, compared to the wild-type organism, naturally occurring V337M mutation of tau protein of mutants leads to age-dependent memory deficits
-
-
?
additional information
?
-
-
CDK-cyclins and CDK inhibitory proteins are involved in the cell cycle regulation and of vascular cell proliferation and migration, as well as in the control of neointimal thickening, modeling, overview
-
-
?
additional information
?
-
-
Cdk5 regulates Akt activation and cell survival through the neuregulin-mediated PI 3-kinase signaling pathway, null mutants show lower phosphatidylinositol 3-kinase activity, Cdk5-p35 mediates neuroprotection
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, and is critical for neuronal survival, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
the CDKs are involved in regulation of cell cycle and neuronal differentiation, cleavage of p35 to p25 occurs in neurons undergoing induced cell death and in brains exposed to ischaemia
-
-
?
additional information
?
-
-
Cdk5 is a modulator of spine morphogenesis
-
-
?
additional information
?
-
-
the CDK2-cyclin E complex is a inducer of S-phase entry and key factor for the initiation of centrosome duplication, that CDK4/6-cyclin D are the proteins that compensates for the loss of CDK2 in the initiation of centrosome duplication
-
-
?
additional information
?
-
-
CDK is involved in control of cell differentiation and organogenesis
-
-
?
additional information
?
-
-
CDKB and CDKA are regulated through phosphorylation and cyclins A and B during the cll cycle, regulation overview
-
-
?
additional information
?
-
the enzyme is a component of maturation-promoting factor
-
-
?
additional information
?
-
-
the enzyme is a component of maturation-promoting factor
-
-
?
additional information
?
-
enzyme is required for mitosis
-
-
?
additional information
?
-
enzyme plays an important role in spermatogenesis
-
-
?
additional information
?
-
Cdk2 protein might be required for entry into the S phase of the cell cycle in FRTL-Tc cells
-
-
?
additional information
?
-
-
CDK5-dependent clustering of endoplasmic reticulum ER and mitochondria during ceramide-mediated neuronal death: neurotoxic calcium transfer from ER to mitochondria is regulated by cyclin-dependent kinase 5-dependent phosphorylation of tau, inhibition of the process leads to cell death
-
-
?
additional information
?
-
-
CDK-cyclins and CDK inhibitory proteins are involved in the cell cycle regulation and of vascular cell proliferation and migration, as well as in the control of neointimal thickening, modeling, overview
-
-
?
additional information
?
-
-
Cdk5 regulates Akt activation and cell survival through the neuregulin-mediated PI 3-kinase signaling pathway, null mutants show lower phosphatidylinositol 3-kinase activity, Cdk5-p35 mediates neuroprotection
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
Cdk5-p35 is negatively regulated by interaction with membranes in brain and liver, mechanism
-
-
?
additional information
?
-
-
cyclin-dependent kinase activity is required for apoptotic death involving the retinoblastoma protein but not inclusion formation in cortical neurons after proteasomal inhibition, Cdk2, Cdk4, and Cdk6 promote the apoptosis induced by lactacystin and other proteasome inhibitors, expression of a defective retinoblastoma protein is neuroprotective
-
-
?
additional information
?
-
-
the CDKs are involved in regulation of cell cycle and neuronal differentiation, cleavage of p35 to p25 occurs in neurons undergoing induced cell death and in brains exposed to ischaemia
-
-
?
additional information
?
-
-
the phosphatidylinositol-linked dopamine receptor is involved in regulation of cdk5 enzyme activity in the brain
-
-
?
additional information
?
-
-
CDK5 induces caspase-independent mitochondrial fission
-
-
?
additional information
?
-
enzyme is required for initiation of meiosis and sporulation
-
-
?
additional information
?
-
negative regulatory factors of the PHO system
-
-
?
additional information
?
-
-
negative regulatory factors of the PHO system
-
-
?
additional information
?
-
Kin28 may be a cyclin dependent kinase which is required for cell proliferation
-
-
?
additional information
?
-
enzyme is required for induction of meiosis
-
-
?
additional information
?
-
-
determination of cyclin specificity of Cdk1 during cell cycle using mutant Cdk1-as1 with an enlarged ATP binding site, overview
-
-
?
additional information
?
-
-
Cdk1 controls timing of vacuole movement and regulates vacuole inheritance
-
-
?
additional information
?
-
-
Pho85 is a proline-directed kinase that preferentially phosphorylates the consensus sequence S/T-P-X-I/L. Cln3 contains two of these sites (Ser449 and Thr520) located precisely at the ends of the PEST region. Cln3 is an in vitro substrate of Pho85, and both proteins interact in vivo, Cln3 is a molecular target of the Pho85 kinase
-
-
?
additional information
?
-
-
Pho85 is a proline-directed kinase that preferentially phosphorylates the consensus sequence S/T-P-X-I/L. Cln3 contains two of these sites (Ser449 and Thr520) located precisely at the ends of the PEST region. Cln3 is an in vitro substrate of Pho85, and both proteins interact in vivo, Cln3 is a molecular target of the Pho85 kinase
-
-
?
additional information
?
-
enzyme is required for both the G1-S and G2-M transitions during mitotic growth, and also for the second meiotic nuclear division
-
-
?
additional information
?
-
-
enzyme is required for both the G1-S and G2-M transitions during mitotic growth, and also for the second meiotic nuclear division
-
-
?
additional information
?
-
the enzyme is required during both G1 and G2 phases of the cell division cycle
-
-
?
additional information
?
-
-
the enzyme is required during both G1 and G2 phases of the cell division cycle
-
-
?
additional information
?
-
csk1 may encode a protein kinase physically associated with mcs2 or alternatively may function as an upstream activator of the mcs2-associated kinase
-
-
?
additional information
?
-
-
Cdk5 regulation, overview, Cdk5 is involved in neuronal migration and phosphorylation of neurofilaments and cytoskeletal proteins, deregulation of Cdk5 occurs in neurodegeneration
-
-
?
additional information
?
-
-
cdc2-related kinase 12 autophosphorylates in vivo
-
-
?
additional information
?
-
enzyme may be involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
enzyme may be involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
enzyme may be involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
enzyme is involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
enzyme is involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
enzyme is involved in controlling aspects of the cell cycle which are linked to the differentiation of the parasite during its complex life cycle
-
-
?
additional information
?
-
-
cdc2-related kinase 12 autophosphorylates in vivo
-
-
?
additional information
?
-
enzyme is required both for entry into S phase and mitosis
-
-
?
additional information
?
-
enzyme is involved in negative regulation of meiotic maturation of Xenopus oocytes
-
-
?
additional information
?
-
-
Cdks are cell cycle regulating enzymes, Cdk1 phosphorylates the anaphase-promoting complex-cyclosome during mitosis, which is a prerequisite for its activity but reduces the anaphase-promoting complex-cyclosome interaction with Cdc20 involving Mad2, the spindle checkpoint requires cyclin-dependent kinase activity, inhibition of Cdk overrides checkpoint-dependent arrest in eggs increasing the interaction of the anaphase-promoting complex-cyclosome with Cdc20, regulation overview
-
-
?
additional information
?
-
-
Cdk-A/cyclin D2 is involved in DNA replication progress and cell proliferation
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
(-)-cis-5,7-dihydroxyphenyl-8-[4-(3-hydroxy-1-methyl)piperidinyl]-4H-1-benzopyran-4-one
-
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]cyclohexane-1,2-diol
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
(2R)-2-{[9-(propan-2-yl)-6-({[4-(pyridin-2-yl)phenyl]methyl}amino)-9H-purin-2-yl]amino}butan-1-ol
-
-
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
(3-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)acetonitrile
-
-
(3-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)methanol
-
-
(3-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]phenyl)acetonitrile
-
41% inhibition at 0.01 mM
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]- purin-2-yl]pyrrolidin-3-ol
-
-
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]-purin-2-yl]pyrrolidin-3-ol
-
-
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)hydrazine trihydrochloride
(4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)acetonitrile
-
-
(4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]phenyl)acetonitrile
-
-
(5Z)-2-(benzylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-(butylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-(cyclopropylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-(methoxyamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-(methylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-(phenylamino)-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[(2,6-dichlorobenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[(2-bromobenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[(2-chlorobenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[(2-methoxybenzyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[(2-phenylethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[(2-pyridin-2-ylethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[(3-hydroxy-2-phenylpropyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[(3-phenylpropyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[(pyridin-2-ylmethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[methyl(thiophen-2-ylmethyl)amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[(1R)-1-benzyl-2-hydroxyethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[(1R)-2-hydroxy-1-phenylethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[(1R)-2-methoxy-1-phenylethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[(1R,2S)-2-phenylcyclopropyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[(1S)-1-benzyl-2-hydroxyethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[(1S)-2-hydroxy-1-phenylethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[2-(2-chlorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[2-(2-ethoxyphenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[2-(2-fluorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[2-(2-methoxyphenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[2-(3-chlorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[2-(3-fluorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[2-(4-bromophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[2-(4-chlorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[2-(4-fluorophenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-2-[[2-(4-methoxyphenyl)ethyl]amino]-5-(quinolin-6-ylmethylidene)-1,3-thiazol-4(5H)-one
-
(5Z)-5-(quinolin-6-ylmethylidene)-2-(thiophen-2-ylmethyl)-1,3-thiazol-4(5H)-one
-
(5Z)-5-(quinolin-6-ylmethylidene)-2-[(2-thiophen-2-ylethyl)amino]-1,3-thiazol-4(5H)-one
-
(5Z)-5-(quinolin-6-ylmethylidene)-2-[(thiophen-2-ylmethyl)amino]-1,3-thiazol-4(5H)-one
-
1,2-di(2-pyridyl)-1H-pyrazolo[3,4-c]pyridazine
1,2-dimethyl-1H-pyrazolo[3,4-c]pyridazine
1,25-dihydroxyvitamin D3
-
inhibition of CDK2 activity by 1,25-dihydroxyvitamin D3 is associated with decreased T160 phosphorylation, a residue whose phosphorylation in the nucleus is essential for CDK2 activity. 1,25-dihydroxyvitamin D3 increases the stability of the cyclin-dependent kinase inhibitor p27KIP1. Ectopic expression of cyclin E is sufficient to overcome 1,25-dihydroxyvitamin D3-mediated cytoplasmic mislocalization of CDK2 and all antiproliferative effects of 1,25-dihydroxyvitamin D3, yet endogenous levels of cyclin E or binding to CDK2 are not affected by 1,25-dihydroxyvitamin D3. Targeting CDK2 to the nucleus of 1,25-dihydroxyvitamin D3-sensitive cancer cells blocked G1 accumulation and growth inhibition by 1,25-dihydroxyvitamin D3
1-(1-acetylpiperidin-4-yl)-8-(cyclopentylamino)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)-3-ethylurea
1-(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)-3-phenylurea
1-(5-cyclobutyl-thiazol-2-yl)-3-isoquinolin-5-yl-urea
-
competitive inhibitor
1-acetyl-3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
1-amino-3H-dibenzo[f,h]pyrazolo[3,4-c]cinnoline
1-benzyl-8-(cyclopentylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]-quinazoline-3-carboxamide
-
-
1-methyl-8-([1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl]amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[(1-methylpiperidin-4-yl)amino]-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[(pyridin-2-ylmethyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[(pyridin-3-ylmethyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[(pyridin-4-ylmethyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[1-(methylsulfonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[1-(phenylcarbonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[1-(phenylsulfonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[2-(morpholin-4-yl)ethyl]amino]-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[2-(piperidin-1-yl)ethyl]amino]-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[3-(4-methylpiperazin-1-yl)benzyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[4-(4-methylpiperazin-1-yl)benzyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-methyl-8-[[4-(methylsulfonyl)benzyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
1-NMPP1
-
inhibits Cdk7, selective inhibition of Cdk7 in G1 prevents activation but not formation of Cdk2/cyclin complexes and delays S phase. Inhibiting Cdk7 in G2 blocks entry to mitosis and disrupts Cdk1/cyclin B complex assembly
1-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]-N,N-dimethyl-L-prolinamide
-
2,2'-[(6-([(4-methoxyphenyl)methyl]-amino)-9-(1-methylethyl)-9H-purin-2-yl)imino]bis(ethanol)
i.e. CVT-313, specific and potent inhibitor. Inhibits the growth of human lung carcinoma cell line A549 in a dose-dependent manner, with an IC50 of 0.0012 mM
-
2,5-hexanedione
-
activities of CDK5 in cerebral cortex of 200 or 400 mg/kg 2,5-hexanedione-treated rats are significantly decreased in both the cytosolic and membrane fractions, CDK5 activities are significantly decreased in the cytosolic fraction of spinal cord cord in 200 and 400 mg/kg 2,5-hexanedione-treated rats
2-(2-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
2-(3-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
2-(3-chloro-4-piperazin-1-yl-phenylamino)-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
2-(3-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
2-(4-aminophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
2-(4-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
2-(4-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
2-biphenyl-4-yl-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
2-[(3,4-dimethoxyphenyl)amino]-8-ethylpyrido[2,3-d]pyrimidin-7(8H)-one
-
2-[(3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-1-yl)methoxy]ethanol
2-[(4-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]piperazin-1-yl)sulfonyl]-2-oxoethanol
-
2-[(4-[4-[(6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]piperazin-1-yl)sulfonyl]-1-(methylsulfanyl)-2-oxoethanol
-
2-[(4-[4-[(6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]piperazin-1-yl)sulfonyl]-2-oxoethanol
-
2-[2-(3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-1-yl)ethoxy]ethanol
2-[4-(4-acetyl-piperazin-1-yl)-phenylamino]-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
2-[4-(diethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
2-[4-(dimethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
-
3-acetamide-1-acetyl-4,5-diphenyl-1H-pyrazolo[3,4-c]-pyridazine
3-acetamide-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
3-amino-1-benzyl-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
3-amino-4,5-bis(p-aminophenyl)-1H-pyrazolo[3,4-c]-pyridazine
3-amino-4,5-bis(p-methoxyphenyl)-1H-pyrazolo[3,4-c]-pyridazine
3-amino-4,5-bis(p-nitrophenyl)-1H-pyrazolo[3,4-c]pyridazine
3-amino-4,5-bis(p-tert-butylphenyl)-1H-pyrazolo[3,4-c]-pyridazine
3-amino-4,5-bis(p-trifluoromethylphenyl)-1H-pyrazolo-[3,4-c]pyridazine
3-amino-4,5-di(2-furyl)-1H-pyrazolo[3,4-c]pyridazine
3-amino-4-phenyl-1H-pyrazolo[3,4-c]pyridazine
3-amino-5-(2-furyl)-1H-pyrazolo[3,4-c]pyridazine
3-amino-5-methyl-4-phenyl-1H-pyrazolo[3,4-c]pyridazine
3-amino-5-phenyl-1H-pyrazolo[3,4-c]pyridazine
3-isopropyl-5(R)-(2-hydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5(R)-[1-(hydroxymethyl)propyl]amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5,7-di[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-(2,3-dihydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-(2-aminoethyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-(2-hydroxy-2-methylpropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-(2-hydroxyethyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-(3-amino-2-hydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-(4-methoxybenzyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-(N-morpholinyl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-(piperazin-1-yl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-(thiomorpholinyl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-(trans-2-aminocyclohexyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-(trans-4-aminocyclohexyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-methylsulfanyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-methylsulfonyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-[2-(2-hydroxyethyl)piperidin-1-yl]-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-[2-(dimethylamino)ethyl]amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-5-[4-(2-hydroxyethyl)piperazin-1-yl]-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
-
-
3-[[(2,2-dioxido-1,3-dihydro-2-benzothien-5-yl)amino]methylene]-5-(1,3-oxazol-5-yl)-1,3-dihydro-2H-indol-2-one
-
-
3-[[4-([[amino(imino)methyl]amino]sulfonyl)anilino]methylene]-2-oxo-2,3-dihydro-1H-indole
-
-
4-(1,3-benzothiazol-2-yl)-N-(1,3-thiazol-2-yl)thiophene-2-sulfonamide
-
4-(1,3-benzothiazol-2-yl)-N-(2-fluoroethyl)thiophene-2-sulfonamide
poor inhibition of cdk5/p25
4-(1,3-benzothiazol-2-yl)-N-(4,5-dimethyl-1,3-thiazol-2-yl)thiophene-2-sulfonamide
-
4-(1,3-benzothiazol-2-yl)-N-(4-methylpyridin-2-yl)thiophene-2-sulfonamide
-
4-(1,3-benzothiazol-2-yl)-N-(5-hydroxypyridin-2-yl)thiophene-2-sulfonamide
-
4-(1,3-benzothiazol-2-yl)-N-(pyridin-2-ylmethyl)thiophene-2-sulfonamide
-
4-(1,3-benzothiazol-2-yl)-N-hydroxythiophene-2-sulfonamide
-
4-(1,3-benzothiazol-2-yl)-N-[5-(morpholin-4-yl)pyridin-2-yl]thiophene-2-sulfonamide
-
4-(1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
binds to Ile10 and Asp86 in the active site of cdk2
4-(1,4-dioxo-1,4-dihydro-naphthalen-2-ylamino)-N-(2-hydroxy-ethyl)-benzenesulfonamide
-
-
4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine
-
4-(6-acetyl-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
poor inhibition of cdk2/cyclin E
4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-benzenesulfonamide
-
-
4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2,3-dihydroxypropyl)-benzenesulfonamide
-
-
4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2-hydroxyethyl)benzenesulfonamide
-
-
4-(6-chloro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
-
4-(6-fluoro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
-
4-(6-methyl-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
-
4-(6-nitro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
-
4-amino-1-tert-butyl-3-(1'-naphthylmethyl)pyrazolo[3,4-d]pyrimidine
-
-
4-chloro-N-(cis-3-[4-[(naphthalen-1-ylacetyl)amino]-1H-imidazol-1-yl]cyclobutyl)benzamide
-
4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]-N-(2-methoxyethyl)benzenesulfonamide
-
4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide
-
4-[(4-imidazo[1,2-b]pyridazin-3-ylpyrimidin-2-yl)amino]-N-methylbenzenesulfonamide
-
4-[2-(5-bromo-2-oxo-1,2-dihydro-3H-indol-3-ylidene)hydrazino]benzenesulfonamide
-
-
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-(4-[[3-(1,3-oxazetidin-3-yl)propyl]sulfonyl]phenyl)pyrimidin-2-amine
-
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine
-
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(propylsulfonyl)phenyl]pyrimidin-2-amine
-
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl]pyrimidin-2-amine
-
4-[4-(8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido-[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperazine-1-carbaldehyde
-
-
4-[4-(8-cyclopentyl-5-methyl-7-oxo-7,8-dihydro-pyrido-[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[4-(8-cyclopentyl-7-oxo-5-trifluoromethyl-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)-phenyl]-piperazine-1-carboxylic acid tert-butyl ester
-
-
4-[7-(4-chloro-3-fluorophenyl)-1,3-benzothiazol-2-yl]thiophene-2-sulfonamide
-
4-[7-(4-fluorophenyl)-1,3-benzothiazol-2-yl]thiophene-2-sulfonamide
poor inhibition of cdk2/cyclin E
4-[[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino]-N-(1,3-thiazol-2-yl)benzenesulfonamide
-
-
4-[[(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)methyl]amino]-N-(2-pyridinyl)benzenesulfonamide
-
-
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)-N-methylbenzenesulfonamide
-
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-methylbenzenesulfonamide
-
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-[3-(1-methylethoxy)propyl]benzenesulfonamide
-
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
-
4-[[4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
4-[[4-(1-cyclopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N,N-diethylbenzamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N,N-diethylbenzenesulfonamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N,N-dimethylbenzamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N-(2-hydroxypropyl)benzenesulfonamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N-(tetrahydrofuran-2-ylmethyl)benzenesulfonamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N-1,3-thiazol-2-ylbenzenesulfonamide
-
-
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenol
-
-
4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]-N,N-diethylbenzamide
-
29% inhibition at 0.001 mM
4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]-N,N-diethylbenzenesulfonamide
-
33% inhibition at 0.01 mM
4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]-N,N-dimethylbenzamide
-
49% inhibition at 0.1 mM
4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]benzamide
-
-
5,6-dichloro-1-beta-D-ribofuranosyl benzimidazole
-
cdk9 inhibitor
5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole
-
-
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole
-
specific CDK7 and 9 inhibition drives resolution of neutrophil-dominant inflammation
5-fluoro-6,8-dimethyl-N-(4-morpholin-4-ylphenyl)-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
6,7-dimethoxy-N-(3hydroxyphenyl)quinazolin-4-amine
-
-
6,8-dimethyl-N-(4-morpholin-4-ylphenyl)-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
6,8-dimethyl-N-[4-[4-(methylsulfonyl)piperazin-1-yl]phenyl]-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
6-(cyclohexylmethoxy)-N2-(3-methoxyphenyl)-5-nitrosopyrimidine-2,4-diamine
-
-
6-(cyclohexylmethoxy)-N2-(4-methoxyphenyl)-5-nitrosopyrimidine-2,4-diamine
-
-
6-(cyclohexylmethoxy)-N2-[3-(methylsulfanyl)phenyl]-5-nitrosopyrimidine-2,4-diamine
-
-
6-(cyclohexylmethoxy)-N2-[3-(methylsulfanyl)phenyl]pyrimidine-2,4-diamine
-
-
6-(cyclohexylmethoxy)-N2-[4-(methylsulfanyl)phenyl]-5-nitrosopyrimidine-2,4-diamine
-
-
6-acetyl-8-cyclopentyl-5-methyl-2-(4-piperazin-1-ylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
6-bromo-8-cyclopentyl-5-methyl-2-(4-piperazin-1-ylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
6-chloro-8-cyclopentyl-5-methyl-2-(4-piperazin-1-ylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
6-dimethylamino purine
-
potent inhibitor of CDK1/cyclin B
8-(1-ethyl-propyl)-5-methyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-(benzylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclohexylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]-quinazoline-3-carboxamide
-
-
8-(cyclohexylamino)-N-1-dimethyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-(2-hydroxyethyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-(4-methoxyphenyl)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-(4-sulfamoylphenyl)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-(pyridin-2-yl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-1-phenyl-4,5-dihydro-1H-pyrazolo[4,3-h]-quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-N-1-dimethyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-N-hydroxy-N,1-dimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-N-methyl-1-(1-methylpiperidin-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-N-[1-(dimethylamino)propan-2-yl]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-(cyclopentylamino)-N-[2-(dimethylamino)ethyl]-N-1-dimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-amino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-cyclopentyl-2-(4-morpholin-4-yl-phenylamino)-8Hpyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-(4-piperazin-1-yl-phenylamino)-5-trifluoromethyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-(4-piperazin-1-yl-phenylamino)-8Hpyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-(4-piperidin-1-yl-phenylamino)-8Hpyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-(4-[1,4]diazepan-1-yl-phenylamino)-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-[4-(3,3-dimethyl-piperazin-1-yl)-phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-[4-(3,5-dimethyl-piperazin-1-yl)-phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-[4-(3-hydroxy-pyrrolidin-1-yl)-phenylamino]-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-2-{4-[4-(3-hydroxy-propyl)-piperidin-1-yl]-phenylamino}-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5,6-dimethyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-ethyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-methyl-2-(4-morpholin-4-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-methyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-methyl-2-(4-piperidin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-methyl-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-5-methyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid
-
-
8-cyclopentyl-5-methyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid ethyl ester
-
-
8-cyclopentyl-5-methyl-7-oxo-2-(4-piperazin-1-yl-phenylamino)-7,8-dihydro-pyrido[2,3-d]pyrimidine-6-carboxylic acid methyl ester
-
-
8-cyclopentyl-6-ethyl-5-methyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-6-fluoro-5-methyl-2-(4-piperazin-1-ylphenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-cyclopentyl-6-iodo-5-methyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-ethyl-2-[4-(4-methylpiperazin-1-yl)phenylamino]-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-isopropyl-5-methyl-2-(4-piperazin-1-yl-phenylamino)-8H-pyrido[2,3-d]pyrimidin-7-one
-
-
8-[(1-acetylpiperidin-4-yl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[(1-acetylpiperidin-4-yl)amino]-N,1-dimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[(1-acetylpiperidin-4-yl)amino]-N,1-dimethyl-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[(1-ethylpiperidin-4-yl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[(2-hydroxyethyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
-
-
8-[(3-methoxybenzyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[(4-bromobenzyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
-
-
8-[(4-methoxybenzyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
8-[[4-(acetylamino)benzyl]amino]-1-methyl-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
actinomycin D
-
is less effective than 1-NMPP1 at inhibiting Cdk2 T loop phosphorylation
AMP
-
competitive inhibitor
apigenin
-
a flavonoid inhibitor of CDK6, CDK5, and CDK1
CDK inhibitory proteins
-
CDK1 inhibitor III
-
i.e. ethyl(6-hydroxy-4-phenylbenzo[4,5]furo[2,3-b])pyridine-3-carboxylate, inhibition of IE63 protein phosphorylation at Ser224 leads to exclusive localization of IE63 protein in the host nucleus
Cdk2DN
-
inhibition of Cdk2, induces phosphorylation of ataxia-telangiectasia mutated substrates
-
chrysin
-
a flavonoid inhibitor of CDK6, CDK5, and CDK1
Cks1
-
Cks 1 protein inactivates Cdk2, activation of Chk1 leads to inactivation of Cdk2 by promoting phosphorylation-dependent turnover of the Cdk activating phosphatase Cdc25A
-
CVT-313
-
inhibitor used in treatment of neointimal hyperplasia, IC50 for CDK1 is 0.004 mM, for CDK2 0.0005 mM, and for CDK4 0.215 mM
cyclin D1
-
inhibits the association and activation of androgen receptor by CDK6
-
cyclin-dependent kinase inhibitor 1B
-
protein CDKN1B, also called p27kip1
-
cyclin-dependent kinase inhibitor p27KIP1
-
-
-
DN-CDK2
suppresses CDK2 activity and partially increases erlotinib sensitivity
-
E2F1 peptide
-
81PALGRPPVKRRLDLE95
-
erlotinib
erlotinib treatment of breast cancer cells suppresses CDK2 activity; suppresses CDK2 activity, which is critical for cellular sensitivity to erlotinib, regardless of EGFR expression level. CDK1, CDK4 and CDK6 is not associated with erlotinib sensitivity
ethyl 4-[[1-methyl-3-(methylcarbamoyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazolin-8-yl]amino]piperidine-1-carboxylate
-
-
ethyl [2-([[4-(1,3-benzothiazol-2-yl)thiophen-2-yl]sulfonyl]amino)-1,3-thiazol-4-yl]acetate
-
FAALS
five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex
fascaplysin
-
CDK4- and CDK6-specific inhibitor
fisetin
-
a flavonol inhibitor of CDK6, CDK5, and CDK1, binding structure with CDK6 involving V101, E61, K43, D163, and E99 of CDK6, overview
ginsenoside F1
-
noncompetitive inhibition
ginsenoside Rb1
-
noncompetitive inhibition
ginsenoside Re
-
noncompetitive inhibition
ginsenoside Rf
-
noncompetitive inhibition
ginsenoside Rg1
-
noncompetitive inhibition
ginsenoside Rg2
-
noncompetitive inhibition
ginsenoside Rh1
-
noncompetitive inhibition
H1PAla
-
noncompetitive inhibitor
H1PPO4
-
noncompetitive inhibitor
IkappaBalpha
-
human protein, competes with INK4 proteins for binding sites on CDK4, CDK4 is bound at the N-terminal ankyrin repeats, while the C-terminal ankyrin repeats bind NF-kappaB, structure analysis
-
indirubin-5-sulfonic acid
-
-
insulin-like growth factor binding protein-3
-
decreases the phosphorylation activity of CDK2 and CDK4
-
kaempferol
-
a less potent flavonoid inhibitor of CDK6, CDK5, and CDK1
kenpaullone
-
78% inhibition of CDK2 at 0.01 mM
LAALS
five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex
LiCl
-
slight inhibition of T231 phosphorylation by p25-Cdk5 kinase complex
luteolin
-
a flavonoid inhibitor of CDK5 and CDK1
membranes
-
of brain and liver, Cdk5-p35 is negatively regulated by interaction with membranes, mechanism
-
N-(1-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]azetidin-3-yl)acetamide
-
N-(2-methoxyethyl)-4-([4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino)benzenesulfonamide
-
N-(2-methoxyethyl)-4-([4-[2-methyl-1-(2-methylpropyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino)benzenesulfonamide
-
N-(2-methoxyethyl)-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
-
N-(3-{[5-chloro-4-(1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)-4-{[(2E)-4-(dimethylamino)but-2-enoyl]amino}benzamide
-
-
N-(4-[4-[(2-methoxyethyl)sulfonyl]piperazin-1-yl]phenyl)-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
N-(4-[[3-(dimethylamino)propyl]sulfonyl]phenyl)-4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-amine
-
N-(4-[[3-(dimethylamino)propyl]sulfonyl]phenyl)-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
-
N-(5-nitro-1H-indazol-3-yl)-2-phenylacetamide
-
N-(6-amino-pyrimidin-4-yl)-sulfanilic acid amide
-
-
N-1-dimethyl-8-([1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl]amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-1-dimethyl-8-[(1-methylpiperidin-4-yl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-1-dimethyl-8-[[1-(methylsulfonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-1-dimethyl-8-[[1-(phenylcarbonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-benzyl-8-(cyclopentylamino)-N-hydroxy-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-cyclohexyl-8-(cyclopentylamino)-N-hydroxy-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
-
-
N-methyl-4-[[(2-oxo-1,2-dihydro-3H-indol-3-ylidene)methyl]amino]benzenesulfonamide
-
-
N-methyl-[4-[2-(7-oxo-6,7-dihydro-8H-[1,3]thiazolo[5,4-e]indol-8-ylidene)hydrazino]phenyl]methanesulfonamide
-
-
N-[(3R)-1-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]pyrrolidin-3-yl]acetamide
-
N-[(9bR)-5-oxo-2,3,5,9b-tetrahydro-1H-pyrrolo[2,1-alpha]isoindol-9-yl]-N'-pyridin-2-yl urea
-
-
N-[(9bR)-5-oxo-2,3,5,9b-tetrahydro-1H-pyrrolo[2,1-alpha]isoindol-9-yl]-N'-{5-[(2S)-pyrrolidin-2-yl]-1H-pyrazol-3-yl urea
-
-
N-[2-(1-aminohydrazino)ethyl]-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
-
N-[2-(dimethylamino)ethyl]-4-[(4-imidazo[1,2-b]pyridazin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide
-
N-[4-(4-[[(diethylamino)acetyl]sulfonyl]piperazin-1-yl)phenyl]-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
N-[4-(4-[[(dimethylamino)acetyl]sulfonyl]piperazin-1-yl)phenyl]-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
N-[4-(4-[[2-(dimethylamino)ethyl]sulfonyl]piperazin-1-yl)phenyl]-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
-
N-[4-(benzylsulfonyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
-
N-[4-[(2-methoxyethyl)sulfonyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-fluorophenyl)acetamide
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-methylphenyl)acetamide
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-fluorophenyl)acetamide
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-hydroxyphenyl)acetamide
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-methylphenyl)acetamide
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-piperidin-1-ylphenyl)acetamide
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-pyridin-4-ylphenyl)acetamide
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-1-ylacetamide
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-2-ylacetamide
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-phenylacetamide
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfanyl)phenyl]acetamide
-
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfonyl)phenyl]acetamide
-
N-[5-(2,5-dioxoimidazolidin-1-yl)-1H-indazol-3-yl]-2-phenylacetamide
-
N-[5-(2-oxopiperidin-1-yl)-1H-indazol-3-yl]-2-phenylacetamide
-
N-[5-(2-oxopyrrolidin-1-yl)-1H-indazol-3-yl]-2-phenylacetamide
-
N-[5-(dibutylamino)-1H-indazol-3-yl]-2-phenylacetamide
-
N-[5-(diethylamino)-1H-indazol-3-yl]-2-phenylacetamide
-
N-[5-(dipropylamino)-1H-indazol-3-yl]-2-phenylacetamide
-
N-[5-(ethylamino)-1H-indazol-3-yl]-2-phenylacetamide
-
N2-(3-bromophenyl)-6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine
-
-
N2-(3-bromophenyl)-6-(cyclohexylmethoxy)pyrimidine-2,4-diamine
-
-
N4-(6-aminopyrimidin-4-yl)-sulfanilamide
-
competitive inhibitor
N6-Dimethylaminopurine
-
unspecific inhibitor of protein kinases
NMDA
-
inactivates Cdk5 by modulation of Ser67 on the protein phosphatase inhibitor-I, overview
NU6102
-
highly potent and selective ATP-competitive inhibitor of CDK2
oxindole-based compounds
-
highly selective for mrk, IC50 of mrk is 0.0015 mM, low cross-reactivity with PK5 and human CDK1
-
p18
-
wild-type and D76A mutant human INK4 protein, the mutant is only slightly inhibitory, p18 competes with IkappaBalpha for binding sites on CDK4, structure analysis
-
p21CIP
-
as recombinant GST-tagged protein
-
p21Clp1
-
forms a ternary complex with and is negatively regulated by p21Cip1, but not by its truncated fragment p21Cip1-D3
-
p21v1
-
endogenous CDK inhibitor
-
p21v2
-
endogenous CDK inhibitor
-
p27Kip1 cyclin-dependent-kinase inhibitor
-
-
Pho81 phosphoprotein
-
-
-
pRb peptide
-
866SNPPKPLKKLRFDIE880
-
protopanaxatriol
-
noncompetitive inhibition
purvalanol B
-
specific inhibitor of CDK1, 2, 5, and 7
quercetin
-
a less potent flavonoid inhibitor of CDK6, CDK5, and CDK1
RNAi
depletion of PNQALRE by more than 80%, impairs cell proliferation, but fails to arrest the cell cycle at a discrete point
-
RXL motif-containing peptide
-
addition of this peptide significantly reduces substrate phosphorylation by cyclin E-CDK2 and cyclin D2-CDK6
-
shRNA
-
cdk5 shRNA is able to efficiently inhibit the expression of endogenous cdk5
-
Sic1
-
Cdk inhibitor, double-strand break is not efficiently repaired
-
TAACS
five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex
TAALD
five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex
TAALE
five amino-acid peptide inhibitor that is directed toward a noncatalytic binding pocket and which disrupts the cdk2/cyklin E complex
TAALS
disrupts the cdk2/cyclin E complex
tumour suppressor p16INK4a
-
-
[(2R)-1-[[4-(1,3-benzothiazol-2-yl)thiophen-2-yl]sulfonyl]pyrrolidin-2-yl]methanol
poor inhibition of cdk2/cyclin E
[8-(cyclopentylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazolin-3-yl](4-methylpiperazin-1-yl)methanone
-
-
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]cyclohexane-1,2-diol
-
-
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]cyclohexane-1,2-diol
-
-
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
-
-
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
-
-
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
-
-
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
-
-
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
-
-
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
-
-
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is above 0.016 mM
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0040 mM, and for PK5 0.15 mM, only weak inhibition of parasite strains D6 and W2 growth
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.012 mM
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0035 mM, and for PK5 0.13 mM, only weak inhibition of parasite strains D6 and W2 growth
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.030 mM
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0031 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.029 mM
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0014 mM, and for PK5 0.19 mM, only weak inhibition of parasite strains D6 and W2 growth
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for CDK1 is 0.029 mM
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
-
IC50 for mrk is 0.0029 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth
(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)hydrazine trihydrochloride
-
(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)hydrazine trihydrochloride
-
-
(R)-roscovitine
-
-
(R)-roscovitine
-
specific inhibitor of CDK1, 2, 5, and 7
(R)-roscovitine
-
a membrane permeable cyclin-dependent kinase inhibitor
1,2-di(2-pyridyl)-1H-pyrazolo[3,4-c]pyridazine
-
1,2-di(2-pyridyl)-1H-pyrazolo[3,4-c]pyridazine
-
-
1,2-dimethyl-1H-pyrazolo[3,4-c]pyridazine
-
1,2-dimethyl-1H-pyrazolo[3,4-c]pyridazine
-
-
1-(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)-3-ethylurea
-
1-(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)-3-ethylurea
-
-
1-(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)-3-phenylurea
-
1-(4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-3-yl)-3-phenylurea
-
-
1-acetyl-3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
-
1-acetyl-3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
1-amino-3H-dibenzo[f,h]pyrazolo[3,4-c]cinnoline
-
1-amino-3H-dibenzo[f,h]pyrazolo[3,4-c]cinnoline
-
-
2-[(3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-1-yl)methoxy]ethanol
-
2-[(3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-1-yl)methoxy]ethanol
-
-
2-[2-(3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-1-yl)ethoxy]ethanol
-
2-[2-(3-amino-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazin-1-yl)ethoxy]ethanol
-
-
3-acetamide-1-acetyl-4,5-diphenyl-1H-pyrazolo[3,4-c]-pyridazine
-
3-acetamide-1-acetyl-4,5-diphenyl-1H-pyrazolo[3,4-c]-pyridazine
-
-
3-acetamide-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
-
3-acetamide-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-1-benzyl-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
-
3-amino-1-benzyl-4,5-diphenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-4,5-bis(p-aminophenyl)-1H-pyrazolo[3,4-c]-pyridazine
-
3-amino-4,5-bis(p-aminophenyl)-1H-pyrazolo[3,4-c]-pyridazine
-
-
3-amino-4,5-bis(p-methoxyphenyl)-1H-pyrazolo[3,4-c]-pyridazine
-
3-amino-4,5-bis(p-methoxyphenyl)-1H-pyrazolo[3,4-c]-pyridazine
-
-
3-amino-4,5-bis(p-nitrophenyl)-1H-pyrazolo[3,4-c]pyridazine
-
3-amino-4,5-bis(p-nitrophenyl)-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-4,5-bis(p-tert-butylphenyl)-1H-pyrazolo[3,4-c]-pyridazine
-
3-amino-4,5-bis(p-tert-butylphenyl)-1H-pyrazolo[3,4-c]-pyridazine
-
-
3-amino-4,5-bis(p-trifluoromethylphenyl)-1H-pyrazolo-[3,4-c]pyridazine
-
3-amino-4,5-bis(p-trifluoromethylphenyl)-1H-pyrazolo-[3,4-c]pyridazine
-
-
3-amino-4,5-di(2-furyl)-1H-pyrazolo[3,4-c]pyridazine
-
3-amino-4,5-di(2-furyl)-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-4-phenyl-1H-pyrazolo[3,4-c]pyridazine
-
3-amino-4-phenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-5-(2-furyl)-1H-pyrazolo[3,4-c]pyridazine
-
3-amino-5-(2-furyl)-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-5-methyl-4-phenyl-1H-pyrazolo[3,4-c]pyridazine
-
3-amino-5-methyl-4-phenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
3-amino-5-phenyl-1H-pyrazolo[3,4-c]pyridazine
-
3-amino-5-phenyl-1H-pyrazolo[3,4-c]pyridazine
-
-
alsterpaullone
-
95% inhibition of CDK2 at 0.01 mM
BS-181
-
only inhibits CDK2 at concentrations lower than 1 mM, with CDK2 being inhibited 35fold less potently than CDK7
CDK inhibitory proteins
-
members of the family of CDK inhibitory proteins, e.g. INK4 proteins, overview, CKIs may play a role as regulators in neointimal hyperplasia
-
CDK inhibitory proteins
-
members of the family of CDK inhibitory proteins, e.g. INK4 proteins, overview, CKIs may play a role as regulators in neointimal hyperplasia
-
CDK inhibitory proteins
-
members of the family of CDK inhibitory proteins, e.g. INK4 proteins, overview, CKIs may play a role as regulators in neointimal hyperplasia
-
flavopiridol
-
-
flavopiridol
-
an effective flavonoid inhibitor of CDK6, CDK5, and CDK1
flavopiridol
-
specific cyclin-dependent kinase inhibitor
flavopiridol
-
non-specific CDK inhibitor
flavopiridol
-
maximal inhibition at 24 h with doses of 200 nM or higher
flavopiridol
-
a potent CDK9 inhibitor
flavopiridol
-
inhibitor used in treatment of neointimal hyperplasia, IC50 for CDK1 is 0.0005 mM, for CDK2 0.0001 mM, for CDK4 0.000065 mM, for CDK6 0.00006 mM, and for CDK7 0.00011-0.0003 mM
indirubin-3'-monoxime
-
82% inhibition of CDK2 at 0.01 mM
indirubin-3'-monoxime
-
-
INK4 proteins
-
inhibit CDK4
-
INK4 proteins
-
inhibit CDK4
-
INK4 proteins
-
inhibit CDK4
-
isopentenyladenine
-
-
isopentenyladenine
-
potent inhibitor of CDK1/cyclin B
LDC000067
-
highly specific inhibitor for isoform CDK9, i.e. 3-((6-(2-methoxyphenyl)pyrimidin-4-yl)aminophenyl)methane sulfonamide
Olomoucine
-
-
Olomoucine
-
Cdk5 inhibitor, tau protein phosphorylation at S202, S235, and S404 is inhibited to a basal level
Olomoucine
-
decreases by ca. 30% the phosphorylation of parkin
Olomoucine
-
specific inhibitor of CDK1, 2, 5, and 7
p15Ink4b
-
INK4 protein
-
p15Ink4b
-
INK4 protein
-
p15Ink4b
-
INK4 protein
-
p16
-
wild-type and D84A mutant human INK4 protein, the mutant is only slightly inhibitory, p16 has regulatory function on the CDK4/cyclin D2 activity, p16 competes with IkappaBalpha for binding sites on CDK4, structure analysis
p16
-
i.e. p16INK4, inhibits CDK4, not CDK2
p16Ink4a
-
INK4 protein
-
p16Ink4a
-
inhibits the association and activation of androgen receptor by CDK6
-
p16Ink4a
-
as recombinant His-tagged protein
-
p16Ink4a
-
INK4 protein
-
p16Ink4a
-
INK4 protein
-
p18Ink4c
-
INK4 protein
-
p18Ink4c
-
INK4 protein
-
p18Ink4c
-
INK4 protein
-
p19Ink4d
-
INK4 protein
-
p19Ink4d
-
INK4 protein
-
p19Ink4d
-
INK4 protein
-
p21
-
induction of p21 by p53 leads to inhibition of Cdk2 and Cdk1 complexes
-
p21
-
also named WAF1, SD1,or Cip1, specific inhibitor of CDK2, 4 and 6
-
p21 protein
-
i.e. Cip1 or Waf1, a Cdk-inhibitor
-
p21 protein
-
i.e. Cip1 or Waf1, a Cdk-inhibitor
-
p21Cip1
-
inhibits phosphorylation of tumor suppressor Rb
-
p21WAF1/CIP1
-
specific Cdk inhibitor, efficiently prevents etoposide-induced apoptotic cell death
-
p21WAF1/CIP1
-
potent CDK inhibitor
-
p27
-
-
p27
-
endogenous CDK inhibitor
-
p27Kip1
-
-
-
p27Kip1
-
as recombinant GST-tagged protein, formation of p27KIP1-cyclin A-CDK2 complex, the inhibitor interacts with both the cyclin and the CDK, analysis of the p27KIP1 docking site on cyclins, overview. p27KIP1 binds to the cyclin in a shallow groove where the hydrophobic amino acids of the MRAIL helix make multiple van der Waals contacts with p27KIP1
-
purvalanol
-
98% inhibition of CDK2 at 0.01 mM
pyrazolopyridazine
-
roscovitine
-
-
roscovitine
-
inhibition of IE63 protein phosphorylation at Ser224 leads to exclusive localization of IE63 protein in the host nucleus
roscovitine
-
93% inhibition of CDK2 at 0.01 mM
roscovitine
-
complete inhibition of T231 phosphorylation by 25-Cdk5 kinase complex
roscovitine
-
inhibition in vitro and in vivo
roscovitine
-
Cdk5 inhibition induces neurotransmitter release in vivo
roscovitine
-
specific cyclin-dependent kinase inhibitor, inhibits cdk1, cdk2, cdk5, cdk7, and cdk9, no proteasome-dependent inhibition, time course of inhibition after treatment of infected cells in vivo, effects on viral replication, overview
roscovitine
-
inhibits Cdk2 activity which inhibits also the progesterone receptor activity in vivo
roscovitine
-
blocks the motility of prostate cancer cells in a wound healing assay
roscovitine
-
decreases by ca. 30% the phosphorylation of parkin
roscovitine
-
added at 24 h after human cytomegalovirus infection affects the accumulation of specific virus-encoded proteins
roscovitine
-
binds to the ATP binding pocket of Cdk2, preventing phosphate transfer from ATP to the protein substrate
roscovitine
0.02 mM, potent Cdk5 inhibitor
roscovitine
specific inhibitor of CDK1, CDK1, CDK5, CDK7, and CDK9
roscovitine
-
Cdk5-p39 is inhibited by roscovitine at concentrations nearly identical to those that inhibit Cdk5-p35
roscovitine
-
competitive inhibitor
roscovitine
-
inhibits Cdk5 activity, including the p35 phosphorylation activity
roscovitine
-
0.02 mM, potent Cdk5 inhibitor
roscovitine
specific inhibitor of CDK1, CDK1, CDK5, CDK7, and CDK9
roscovitine
-
inhibition of CDK5
simvastatin
-
inhibition of CDK2
simvastatin
-
inhibition of CDK2
simvastatin
-
inhibition of CDK2
siRNA
-
knockdown of cdk5, results in a reduction in primary sensory neurons of the trigeminal ganglia of the peripheral nervous system, 80% loss of cdk5 protein in 10 hpf embryos
-
siRNA
-
blocks the motility of prostate cancer cells in a wound healing assay
-
siRNA
-
inhibition of Cdk2, induces phosphorylation of ataxia-telangiectasia mutated substrates
-
siRNA
-
decreases by ca. 35% the phosphorylation of parkin
-
siRNA
-
knocking down of PFTK1 expression in SH-SY5Y cells, causes cell cycle arrest at G1
-
siRNA
-
knock down of Cdk2
-
SNS-032
-
SNS-032
-
formerly known as BMS-387032, SNS-032 exhibits potent and selective inhibitory activity against Cdk2, Cdk7, and Cdk9
staurosporine
-
staurosporine
-
potent inhibitor of CDK1/cyclin B
SU9516
-
inhibition in vitro and in vivo
tranilast
-
inhibition of CDK2 and CDK4
tranilast
-
inhibition of CDK2 and CDK4
tranilast
-
inhibition of CDK2 and CDK4
additional information
-
inhibitor synthesis and screening, docking study, overview
-
additional information
-
some cyclin-dependent kinases are inactivated by a complex of rapamycin with rapamycin-associated protein and FK506-binding protein
-
additional information
-
regulation by reversible phosphorylation, overview
-
additional information
-
negative feedback regulation mechanism via reduced stability, CDK-cyclin oscillates during the cell cycle, overview
-
additional information
-
no inhibition of the p25-Cdk5 kinase complex by PD98059 and SB203580
-
additional information
-
T-cell protein tyrosine phosphatase phosphorylation by CDK-cyclin is not affected by diverse stress-inducing agents, hyperosmotic shock, cold shock, heat, oxidative stress, nocodazole, and anisomycin, as well as mitogens such as EGF and FBS
-
additional information
-
inhibition mechanism
-
additional information
-
integrin alpha1beta1 regulates phosphorylation of the axonal cytoskeleton protein, development of inhibitory peptides
-
additional information
-
physiological effects of CDK inhibition, overview, CDKs are deactivated by dephosphorylation, protein p27Kip1 mediates CDK2 inhibition
-
additional information
-
analysis of interactions between small molecule inhibitors with the ATP binding pocket of CDK2, determinations of binding structures and design of an inhibitor scaffold, overview
-
additional information
-
IC50 values of pyrido[2,3-d]pyrimidin-7-one inhibitors on Cdk4/cyclin D1, Cdk1/cyclin B, Cdk2/cyclinA, and Cdk2/cyclin E, overview, antiproliferating activity of pyrido[2,3-d]pyrimidin-7-one inhibitors on MDA-MB-435 cells, overview
-
additional information
cell toxicity of the pyrazolo[3,4-c]pyridazine inhibitors on HeLa cells, overview, molecular modeling and analysis of binding structure of inhibitors to CDK2 using the CDK2 crystal structure, PDB code 1hck, modeling of ligand docking to the CDK2 structure, overview
-
additional information
-
structure-function relationship of flavonoid inhibitors, IC50 values, overview
-
additional information
-
enzyme inhibition results in a decrease in virus titers in vivo, overview
-
additional information
-
glutamate triggers the ubiquitination and subsequent degradation of p35 in neurons after autophosphorylation of Cdk5-p35 at p35
-
additional information
-
CDK is inhibited by phosphorylation through somatic Wee1A in M phase
-
additional information
-
CDK2 is inhibited by phosphorylation at Y14 and/or Y15 in the glycine-rich loop causing opening of the substrate binding box and affects binding of ATP
-
additional information
-
inhibition of Cdk2 by inactivation of Cdc25 phosphatases
-
additional information
-
CDK inhibitor p16INK4a fails to interact with PFTK1; p16INK4a fails to interact with PFTK1
-
additional information
acetylation markedly reduces both the kinase function and transcriptional activity
-
additional information
inhibitor synthesis and evaluation of inhibitory potencies with cdk2/cyclin E and cdk5/p25, overview
-
additional information
-
inhibitor synthesis and screening, docking study, overview
-
additional information
-
CDK-inhibitor-cyclin interaction mutational analysis, overview. Analysis of the inhibitor p27KIP1 docking site on cyclins, overview. Loss of p27KIP1 (or p21CIP) binding to the mutant cyclin D2-CDK complex, but not of p16INK4a
-
additional information
-
evaluation of series of pyrazolo[4,3-h]quinazoline-3-carboxamides as inhibitors using diverse protein kinases, the compounds are active against CDK2/cyclin A, overview
-
additional information
-
nonionic detergent to solubilize Cdk5-p35 changes the kinase properties. Cdk1 is inhibited by Thr14/Tyr15 phosphorylation by the Wee1 family of kinases
-
additional information
-
ginsenosides as inhibitors of cyclin-dependent kinase 5/p25, structure-activity relationships, overview. Ginsenosides Rd, F2, Rb3, Rb2, Rg3, Rc, and Rh2 are no inhibitors of Cdk5/p25. No inhibition by protopanaxadiol
-
additional information
-
not inhibited by the CDK inhibitor p21
-
additional information
-
docking of CIP/KIP inhibitors and surface region involved, overview
-
additional information
-
autoregulation by a pseudosubstrate mechanism, overview
-
additional information
-
IC50 values for CDK1-cyclin B with pyrazolo[3,4-c]pyridazine inhibitors, overview
-
additional information
-
no effect by doxycycline on enzyme expression and activity
-
additional information
-
physiological effects of CDK inhibition, overview, CDKs are deactivated by dephosphorylation, protein p27Kip1 mediates CDK2 inhibition
-
additional information
-
enzyme cofactor p35 levels in primary embryonal cortical neurons are reduced by glutamate-induced stimulation of NMDA or kainate receptors through NMDA or kainate, p35 is reduced via proteasomal degradation, reduced p35 leads to inhibition of Cdk5, no inhibition by casein kinase inhibitor CKI-7
-
additional information
-
glutamate triggers the ubiquitination and subsequent degradation of p35 in neurons after autophosphorylation of Cdk5-p35 at p35
-
additional information
-
after irridation of one- or two-cell embryos the cdk1/cyclin B1 complex is blocked
-
additional information
-
dysregulation of Cdk5 occurs with aging and concomitantly with an increase in DNA damage
-
additional information
-
molecular modeling of inhibitor-enzyme interactions
-
additional information
-
physiological effects of CDK inhibition, overview, CDKs are deactivated by dephosphorylation, protein p27Kip1 mediates CDK2 inhibition
-
additional information
-
R-(+)-7-chloro-8-hydroxy-3-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepine, i.e. SCH23390, or the PLCbeta antagonist 1-[6-([17beta-methoxyestra-1,3,5(10)-trien-17-yl]amino)hexyl]-1H-pyrrole-2,5-dione, i.e. U-73122, inhibit cdk5 transactivation by SKF83959 via the brain phosphatidylinositol-linked dopamin receptor, the transactivation is attenuated by calphostin C or by intracellular calcium chelator BAPTA
-
additional information
-
glutamate triggers the ubiquitination and subsequent degradation of p35 in neurons after autophosphorylation of Cdk5-p35 at p35
-
additional information
-
dysregulation of Cdk5 occurs with aging and concomitantly with an increase in DNA damage
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
0.00027 - 0.00087
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]cyclohexane-1,2-diol
0.00018 - 0.0014
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
0.000062 - 0.000225
(2R)-2-{[9-(propan-2-yl)-6-({[4-(pyridin-2-yl)phenyl]methyl}amino)-9H-purin-2-yl]amino}butan-1-ol
0.00015 - 0.0006
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
0.00037 - 0.00101
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
0.033
(3-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)acetonitrile
Homo sapiens
-
with isozyme CDK2
0.000045
(3-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)methanol
Homo sapiens
-
with isozyme CDK2
0.00045 - 0.00065
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]- purin-2-yl]pyrrolidin-3-ol
0.00045
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]-purin-2-yl]pyrrolidin-3-ol
Asteroidea
-
CDK1/cyclin B, pH 7.5, 30°C
0.004 - 0.016
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
0.0035 - 0.012
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
0.0031 - 0.03
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
0.0014 - 0.029
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
0.0029 - 0.029
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
0.000064
(4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenyl)acetonitrile
Homo sapiens
-
with isozyme CDK2
0.024
(4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]phenyl)acetonitrile
Homo sapiens
-
with isozyme CDK2
0.00013 - 0.0142
(R)-roscovitine
0.000007
1-(1-acetylpiperidin-4-yl)-8-(cyclopentylamino)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000023
1-benzyl-8-(cyclopentylamino)-4,5-dihydro-1H-pyrazolo[4,3-h]-quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000012
1-methyl-8-([1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl]amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000351
1-methyl-8-[(1-methylpiperidin-4-yl)amino]-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000087
1-methyl-8-[(pyridin-2-ylmethyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000021
1-methyl-8-[(pyridin-3-ylmethyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000021
1-methyl-8-[(pyridin-4-ylmethyl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000001
1-methyl-8-[[1-(methylsulfonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000001 - 0.000003
1-methyl-8-[[1-(phenylcarbonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
0.000004
1-methyl-8-[[1-(phenylsulfonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000209
1-methyl-8-[[2-(morpholin-4-yl)ethyl]amino]-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.00249
1-methyl-8-[[2-(piperidin-1-yl)ethyl]amino]-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000104
1-methyl-8-[[3-(4-methylpiperazin-1-yl)benzyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000017
1-methyl-8-[[4-(4-methylpiperazin-1-yl)benzyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000038
1-methyl-8-[[4-(methylsulfonyl)benzyl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000046
1-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]-N,N-dimethyl-L-prolinamide
Homo sapiens
with isozyme CDK2
0.00008 - 0.00089
2-(2-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
0.000007 - 0.0018
2-(3-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
0.000034 - 0.00105
2-(3-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
0.000016 - 0.0022
2-(4-aminophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
0.000007 - 0.002
2-(4-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
0.000012 - 0.002
2-(4-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
0.000014 - 0.0022
2-biphenyl-4-yl-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
0.00003 - 0.00054
2-[(3,4-dimethoxyphenyl)amino]-8-ethylpyrido[2,3-d]pyrimidin-7(8H)-one
0.000006
2-[(4-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]piperazin-1-yl)sulfonyl]-2-oxoethanol
Homo sapiens
with isozyme CDK2
0.000017
2-[(4-[4-[(6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]piperazin-1-yl)sulfonyl]-1-(methylsulfanyl)-2-oxoethanol
Homo sapiens
with isozyme CDK2
0.000017
2-[(4-[4-[(6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]piperazin-1-yl)sulfonyl]-2-oxoethanol
Homo sapiens
with isozyme CDK2
0.00004 - 0.001
2-[4-(diethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
0.00001 - 0.00021
2-[4-(dimethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
0.000005 - 0.000021
3-isopropyl-5(R)-(2-hydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000009 - 0.000054
3-isopropyl-5(R)-[1-(hydroxymethyl)propyl]amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.00145 - 0.0036
3-isopropyl-5,7-di[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000012 - 0.000021
3-isopropyl-5-(2,3-dihydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000008 - 0.000018
3-isopropyl-5-(2-aminoethyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000001 - 0.000009
3-isopropyl-5-(2-hydroxy-2-methylpropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000031 - 0.000049
3-isopropyl-5-(2-hydroxyethyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000017 - 0.000051
3-isopropyl-5-(3-amino-2-hydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.001486 - 0.004415
3-isopropyl-5-(4-methoxybenzyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000005 - 0.000018
3-isopropyl-5-(N-morpholinyl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.00005 - 0.000119
3-isopropyl-5-(piperazin-1-yl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000061 - 0.000114
3-isopropyl-5-(thiomorpholinyl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000044 - 0.000046
3-isopropyl-5-(trans-2-aminocyclohexyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000096 - 0.000179
3-isopropyl-5-(trans-4-aminocyclohexyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000048 - 0.000229
3-isopropyl-5-methylsulfanyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.00007 - 0.000165
3-isopropyl-5-methylsulfonyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000024 - 0.000037
3-isopropyl-5-[2-(2-hydroxyethyl)piperidin-1-yl]-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000467 - 0.002136
3-isopropyl-5-[2-(dimethylamino)ethyl]amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000132 - 0.000422
3-isopropyl-5-[4-(2-hydroxyethyl)piperazin-1-yl]-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.000183 - 0.000197
3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
0.001764 - 0.00548
4-(1,3-benzothiazol-2-yl)-N-(1,3-thiazol-2-yl)thiophene-2-sulfonamide
0.00822
4-(1,3-benzothiazol-2-yl)-N-(4,5-dimethyl-1,3-thiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.008274
4-(1,3-benzothiazol-2-yl)-N-(4-methylpyridin-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.00994
4-(1,3-benzothiazol-2-yl)-N-(5-hydroxypyridin-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.00547 - 0.00672
4-(1,3-benzothiazol-2-yl)-N-(pyridin-2-ylmethyl)thiophene-2-sulfonamide
0.00742
4-(1,3-benzothiazol-2-yl)-N-hydroxythiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.007704
4-(1,3-benzothiazol-2-yl)-N-[5-(morpholin-4-yl)pyridin-2-yl]thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.000551 - 0.0045
4-(1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
0.000023
4-(1-ethyl-2-methyl-1H-imidazol-5-yl)-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.00631
4-(6-acetyl-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.000001
4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-benzenesulfonamide
Homo sapiens
-
-
0.0000008 - 0.000034
4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2,3-dihydroxypropyl)-benzenesulfonamide
0.0000007
4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2-hydroxyethyl)benzenesulfonamide
Homo sapiens
-
-
0.000355 - 0.00086
4-(6-chloro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
0.000331 - 0.00072
4-(6-fluoro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
0.000226 - 0.00126
4-(6-methyl-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
0.000452 - 0.00127
4-(6-nitro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
0.000006 - 0.000204
4-chloro-N-(cis-3-[4-[(naphthalen-1-ylacetyl)amino]-1H-imidazol-1-yl]cyclobutyl)benzamide
0.000012
4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]-N-(2-methoxyethyl)benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.000002
4-[(4-imidazo[1,2-a]pyridin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.000003
4-[(4-imidazo[1,2-b]pyridazin-3-ylpyrimidin-2-yl)amino]-N-methylbenzenesulfonamide
Homo sapiens
with isozyme CDK2
0.000033 - 0.00021
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-(4-[[3-(1,3-oxazetidin-3-yl)propyl]sulfonyl]phenyl)pyrimidin-2-amine
0.000006 - 0.00045
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine
0.000008
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(propylsulfonyl)phenyl]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.000013 - 0.00053
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl]pyrimidin-2-amine
0.000492 - 0.000672
4-[7-(4-chloro-3-fluorophenyl)-1,3-benzothiazol-2-yl]thiophene-2-sulfonamide
0.00678
4-[7-(4-fluorophenyl)-1,3-benzothiazol-2-yl]thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.0004
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)-N-methylbenzenesulfonamide
Homo sapiens
with isozyme CDK2
0.000008 - 0.0056
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
0.000003
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-methylbenzenesulfonamide
Homo sapiens
with isozyme CDK2
0.000006
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-[3-(1-methylethoxy)propyl]benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.000011
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.000003
4-[[4-(1-cyclopentyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
Homo sapiens
with isozyme CDK2, IC50 less than 0.000003 mM
0.000083 - 0.009
4-[[4-(1-cyclopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
0.000004 - 0.0013
4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
0.0002
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N,N-diethylbenzamide
Homo sapiens
-
with isozyme CDK2
0.000086
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N,N-diethylbenzenesulfonamide
Homo sapiens
-
with isozyme CDK2
0.00008
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N,N-dimethylbenzamide
Homo sapiens
-
with isozyme CDK2
0.0000013
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N-(2-hydroxypropyl)benzenesulfonamide
Homo sapiens
-
with isozyme CDK2
0.0000081
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N-(tetrahydrofuran-2-ylmethyl)benzenesulfonamide
Homo sapiens
-
with isozyme CDK2
0.000019
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]-N-1,3-thiazol-2-ylbenzenesulfonamide
Homo sapiens
-
with isozyme CDK2
0.000016
4-[[4-amino-6-(cyclohexylmethoxy)-5-nitrosopyrimidin-2-yl]amino]phenol
Homo sapiens
-
with isozyme CDK2
0.059
4-[[4-amino-6-(cyclohexylmethoxy)pyrimidin-2-yl]amino]benzamide
Homo sapiens
-
with isozyme CDK2
0.001942
5,6-dichloro-1-beta-D-ribofuranosyl-benzimidazole
Homo sapiens
-
isoform CDK9, at pH 7.5 and 37°C
0.000008
5-fluoro-6,8-dimethyl-N-(4-morpholin-4-ylphenyl)-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.000009
6,8-dimethyl-N-(4-morpholin-4-ylphenyl)-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.000003
6,8-dimethyl-N-[4-[4-(methylsulfonyl)piperazin-1-yl]phenyl]-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2, IC50 less than 0.000003 mM
0.00034
6-(cyclohexylmethoxy)-N2-(3-methoxyphenyl)-5-nitrosopyrimidine-2,4-diamine
Homo sapiens
-
with isozyme CDK2
0.000215
6-(cyclohexylmethoxy)-N2-(4-methoxyphenyl)-5-nitrosopyrimidine-2,4-diamine
Homo sapiens
-
-
0.0004
6-(cyclohexylmethoxy)-N2-[3-(methylsulfanyl)phenyl]-5-nitrosopyrimidine-2,4-diamine
Homo sapiens
-
with isozyme CDK2
0.06
6-(cyclohexylmethoxy)-N2-[3-(methylsulfanyl)phenyl]pyrimidine-2,4-diamine
Homo sapiens
-
with isozyme CDK2
0.00012
6-(cyclohexylmethoxy)-N2-[4-(methylsulfanyl)phenyl]-5-nitrosopyrimidine-2,4-diamine
Homo sapiens
-
with isozyme CDK2
0.000051
8-(benzylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000004
8-(cyclohexylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]-quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000039
8-(cyclohexylamino)-N-1-dimethyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000005 - 0.000006
8-(cyclopentylamino)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
0.000008
8-(cyclopentylamino)-1-(2-hydroxyethyl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000006
8-(cyclopentylamino)-1-(4-methoxyphenyl)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000005
8-(cyclopentylamino)-1-(4-sulfamoylphenyl)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000052
8-(cyclopentylamino)-1-(pyridin-2-yl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000002
8-(cyclopentylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.00002
8-(cyclopentylamino)-1-phenyl-4,5-dihydro-1H-pyrazolo[4,3-h]-quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000097
8-(cyclopentylamino)-N-1-dimethyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000175
8-(cyclopentylamino)-N-hydroxy-N,1-dimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000059
8-(cyclopentylamino)-N-methyl-1-(1-methylpiperidin-4-yl)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.00176
8-(cyclopentylamino)-N-[1-(dimethylamino)propan-2-yl]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.01
8-(cyclopentylamino)-N-[2-(dimethylamino)ethyl]-N-1-dimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.01
8-amino-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000002
8-[(1-acetylpiperidin-4-yl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000032
8-[(1-acetylpiperidin-4-yl)amino]-N,1-dimethyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000149
8-[(1-ethylpiperidin-4-yl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000019
8-[(2-hydroxyethyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000066
8-[(3-methoxybenzyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000081
8-[(4-bromobenzyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo-[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000058
8-[(4-methoxybenzyl)amino]-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000013
8-[[4-(acetylamino)benzyl]amino]-1-methyl-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000035 - 0.01
alsterpaullone
0.00002 - 0.000033
aminopurvalanol
0.00509
ethyl [2-([[4-(1,3-benzothiazol-2-yl)thiophen-2-yl]sulfonyl]amino)-1,3-thiazol-4-yl]acetate
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.00035 - 0.1
fascaplysin
0.0000052 - 0.0005
flavopiridol
0.0069
ginsenoside F1
Homo sapiens
-
pH 7.5, 37°C
0.02496
ginsenoside Rb1
Homo sapiens
-
pH 7.5, 37°C
0.00901
ginsenoside Re
Homo sapiens
-
pH 7.5, 37°C
0.00976
ginsenoside Rf
Homo sapiens
-
pH 7.5, 37°C
0.00785
ginsenoside Rg1
Homo sapiens
-
pH 7.5, 37°C
0.0108
ginsenoside Rg2
Homo sapiens
-
pH 7.5, 37°C
0.00728
ginsenoside Rh1
Homo sapiens
-
pH 7.5, 37°C
0.000022 - 0.0006
hymenialdisine
0.00426
LAALS
Homo sapiens
-
0.000044
LDC000067
Homo sapiens
-
isoform CDK9, at pH 7.5 and 37°C
0.000026 - 0.00078
meriolin
0.0000005
N-(1-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]azetidin-3-yl)acetamide
Homo sapiens
with isozyme CDK2
0.000001 - 0.0002
N-(2-methoxyethyl)-4-([4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino)benzenesulfonamide
0.000015
N-(2-methoxyethyl)-4-([4-[2-methyl-1-(2-methylpropyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino)benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.00068 - 0.0086
N-(2-methoxyethyl)-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
0.000003
N-(4-[4-[(2-methoxyethyl)sulfonyl]piperazin-1-yl]phenyl)-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2, IC50 less than 0.000003 mM
0.000295
N-(4-[[3-(dimethylamino)propyl]sulfonyl]phenyl)-4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.000036 - 0.00014
N-(4-[[3-(dimethylamino)propyl]sulfonyl]phenyl)-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
0.002
N-(5-nitro-1H-indazol-3-yl)-2-phenylacetamide
Homo sapiens
with isozyme CDK2
0.001122
N-1-dimethyl-8-([1-[(4-methylpiperazin-1-yl)carbonyl]piperidin-4-yl]amino)-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.004585
N-1-dimethyl-8-[(1-methylpiperidin-4-yl)amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000002 - 0.000005
N-1-dimethyl-8-[[1-(methylsulfonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
0.000025
N-1-dimethyl-8-[[1-(phenylcarbonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.001372
N-benzyl-8-(cyclopentylamino)-N-hydroxy-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000296
N-cyclohexyl-8-(cyclopentylamino)-N-hydroxy-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.0000003
N-[(3R)-1-[4-[(5-fluoro-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-yl)amino]phenyl]pyrrolidin-3-yl]acetamide
Homo sapiens
with isozyme CDK2, IC50 above 0.0000003 mM
0.000025
N-[2-(1-aminohydrazino)ethyl]-4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.000008
N-[2-(dimethylamino)ethyl]-4-[(4-imidazo[1,2-b]pyridazin-3-ylpyrimidin-2-yl)amino]benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.000016
N-[4-(4-[[(dimethylamino)acetyl]sulfonyl]piperazin-1-yl)phenyl]-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.000003
N-[4-(4-[[2-(dimethylamino)ethyl]sulfonyl]piperazin-1-yl)phenyl]-6,8-dimethyl-5,6-dihydroimidazo[1',5':1,2]pyrido[3,4-d]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.000019 - 0.0015
N-[4-(benzylsulfonyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
0.000014 - 0.00049
N-[4-[(2-methoxyethyl)sulfonyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
0.00003 - 0.00071
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-fluorophenyl)acetamide
0.00001 - 0.004
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-methylphenyl)acetamide
0.00005 - 0.003
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-fluorophenyl)acetamide
0.000009 - 0.00175
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-hydroxyphenyl)acetamide
0.000007 - 0.0018
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-methylphenyl)acetamide
0.00003 - 0.00075
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-piperidin-1-ylphenyl)acetamide
0.00003 - 0.00133
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-pyridin-4-ylphenyl)acetamide
0.00002 - 0.003
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-1-ylacetamide
0.000009 - 0.0016
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-2-ylacetamide
0.000036 - 0.0037
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-phenylacetamide
0.00001 - 0.0013
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfanyl)phenyl]acetamide
0.000022 - 0.0014
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfonyl)phenyl]acetamide
0.002
N-[5-(2,5-dioxoimidazolidin-1-yl)-1H-indazol-3-yl]-2-phenylacetamide
Homo sapiens
with isozyme CDK2
0.0071
N-[5-(2-oxopiperidin-1-yl)-1H-indazol-3-yl]-2-phenylacetamide
Homo sapiens
with isozyme CDK2
0.00017
N-[5-(2-oxopyrrolidin-1-yl)-1H-indazol-3-yl]-2-phenylacetamide
Homo sapiens
with isozyme CDK2
0.1
N-[5-(dibutylamino)-1H-indazol-3-yl]-2-phenylacetamide
Homo sapiens
with isozyme CDK2, IC50 above 0.1 mM
0.0002
N-[5-(diethylamino)-1H-indazol-3-yl]-2-phenylacetamide
Homo sapiens
with isozyme CDK2
0.0018
N-[5-(dipropylamino)-1H-indazol-3-yl]-2-phenylacetamide
Homo sapiens
with isozyme CDK2
0.0005
N-[5-(ethylamino)-1H-indazol-3-yl]-2-phenylacetamide
Homo sapiens
with isozyme CDK2
0.0005
N2-(3-bromophenyl)-6-(cyclohexylmethoxy)-5-nitrosopyrimidine-2,4-diamine
Homo sapiens
-
with isozyme CDK2
0.026
N2-(3-bromophenyl)-6-(cyclohexylmethoxy)pyrimidine-2,4-diamine
Homo sapiens
-
with isozyme CDK2
0.0036
N4-(6-aminopyrimidin-4-yl)-sulfanilamide
Homo sapiens
-
in 20 mM MOPS (pH 7.5), at 30°C
0.0000022
NU6027
Homo sapiens
-
-
0.00023
OL567
Homo sapiens
-
CDK1
0.00006 - 0.0198
olomoucine II
0.0015
oxindole-based compounds
Plasmodium falciparum
-
highly selective for mrk, IC50 of mrk is 0.0015 mM, low cross-reactivity with PK5 and human CDK1
-
0.00431
protopanaxatriol
Homo sapiens
-
pH 7.5, 37°C
0.000006 - 0.01
purvalanol B
0.0001 - 0.028
roscovitine
0.0000014
SNS-032
Homo sapiens
-
isoform CDK9, at pH 7.5 and 37°C
0.000006 - 0.01
staurosporine
0.0261
TAALS
Homo sapiens
-
0.00888
[(2R)-1-[[4-(1,3-benzothiazol-2-yl)thiophen-2-yl]sulfonyl]pyrrolidin-2-yl]methanol
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.01
[8-(cyclopentylamino)-1-methyl-4,5-dihydro-1H-pyrazolo[4,3-h]quinazolin-3-yl](4-methylpiperazin-1-yl)methanone
Homo sapiens
-
pH 7.5, 30°C
0.00027
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]cyclohexane-1,2-diol
Homo sapiens
-
CDK5/p25, pH 7.5, 30°C
0.00037
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]cyclohexane-1,2-diol
Homo sapiens
-
CDK9/cyclin T, pH 7.5, 30°C
0.00061
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]cyclohexane-1,2-diol
Homo sapiens
-
CDK2/cyclin A, pH 7.5, 30°C
0.00087
(1S,2R,3R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]cyclohexane-1,2-diol
Asteroidea
-
CDK1/cyclin B, pH 7.5, 30°C
0.00018
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
Homo sapiens
-
CDK5/p25, pH 7.5, 30°C
0.00018
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
Homo sapiens
-
CDK9/cyclin T, pH 7.5, 30°C
0.00087
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
Homo sapiens
-
CDK2/cyclin A, pH 7.5, 30°C
0.0014
(2R)-2-hydroxy-3-[[9-(propan-2-yl)-6-[[4-(pyridin-2-yl)benzyl]amino]-9H-purin-2-yl]amino]propyl L-valinate
Asteroidea
-
CDK1/cyclin B, pH 7.5, 30°C
0.000062
(2R)-2-{[9-(propan-2-yl)-6-({[4-(pyridin-2-yl)phenyl]methyl}amino)-9H-purin-2-yl]amino}butan-1-ol
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000225
(2R)-2-{[9-(propan-2-yl)-6-({[4-(pyridin-2-yl)phenyl]methyl}amino)-9H-purin-2-yl]amino}butan-1-ol
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.00015
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
Homo sapiens
-
CDK9/cyclin T, pH 7.5, 30°C
0.00019
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
Homo sapiens
-
CDK5/p25, pH 7.5, 30°C
0.00048
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
Homo sapiens
-
CDK2/cyclin A, pH 7.5, 30°C
0.0006
(2R)-3-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]propane-1,2-diol
Asteroidea
-
CDK1/cyclin B, pH 7.5, 30°C
0.00037
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
Asteroidea
-
CDK1/cyclin B, pH 7.5, 30°C
0.00082
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
Homo sapiens
-
CDK5/p25, pH 7.5, 30°C
0.00098
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
Homo sapiens
-
CDK2/cyclin A, pH 7.5, 30°C
0.00101
(2S)-4-[[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]purin-2-yl]amino]butane-1,2-diol
Homo sapiens
-
CDK9/cyclin T, pH 7.5, 30°C
0.00045
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]- purin-2-yl]pyrrolidin-3-ol
Homo sapiens
-
CDK9/cyclin T, pH 7.5, 30°C
0.00061
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]- purin-2-yl]pyrrolidin-3-ol
Homo sapiens
-
CDK5/p25, pH 7.5, 30°C
0.00065
(3R,5S)-5-(hydroxymethyl)-1-[9-iso-propyl-6-[[4-(2-pyridyl)phenyl]methylamino]- purin-2-yl]pyrrolidin-3-ol
Homo sapiens
-
CDK2/cyclin A, pH 7.5, 30°C
0.004
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
Plasmodium falciparum
-
IC50 for mrk is 0.0040 mM, and for PK5 0.15 mM, only weak inhibition of parasite strains D6 and W2 growth
0.016
(3Z)-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
Homo sapiens
-
IC50 for CDK1 is above 0.016 mM
0.0035
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
Plasmodium falciparum
-
IC50 for mrk is 0.0035 mM, and for PK5 0.13 mM, only weak inhibition of parasite strains D6 and W2 growth
0.012
(3Z)-3-[2-(4-bromophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
Homo sapiens
-
IC50 for CDK1 is 0.012 mM
0.0031
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
Plasmodium falciparum
-
IC50 for mrk is 0.0031 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth
0.03
(3Z)-5-bromo-3-(2-oxo-2-phenylethylidene)-1,3-dihydro-2H-indol-2-one
Homo sapiens
-
IC50 for CDK1 is 0.030 mM
0.0014
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
Plasmodium falciparum
-
IC50 for mrk is 0.0014 mM, and for PK5 0.19 mM, only weak inhibition of parasite strains D6 and W2 growth
0.029
(3Z)-5-bromo-3-[2-(4-fluorophenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
Homo sapiens
-
IC50 for CDK1 is 0.029 mM
0.0029
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
Plasmodium falciparum
-
IC50 for mrk is 0.0029 mM, and for PK5 0.12 mM, only weak inhibition of parasite strains D6 and W2 growth
0.029
(3Z)-5-bromo-3-[2-(4-methylphenyl)-2-oxoethylidene]-1,3-dihydro-2H-indol-2-one
Homo sapiens
-
IC50 for CDK1 is 0.029 mM
0.00013
(R)-roscovitine
Homo sapiens
-
CDK2
0.00016
(R)-roscovitine
Homo sapiens
-
CDK5
0.00021
(R)-roscovitine
Homo sapiens
-
CDK2/cyclin A, pH 7.5, 30°C
0.00023
(R)-roscovitine
Homo sapiens
-
CDK9/cyclin T, pH 7.5, 30°C
0.00028
(R)-roscovitine
Homo sapiens
-
CDK5/p25, pH 7.5, 30°C
0.00033
(R)-roscovitine
Asteroidea
-
CDK1/cyclin B, pH 7.5, 30°C
0.00045
(R)-roscovitine
Homo sapiens
-
CDK1
0.00049
(R)-roscovitine
Homo sapiens
-
CDK7
0.00074
(R)-roscovitine
Homo sapiens
-
CDK9
0.0142
(R)-roscovitine
Homo sapiens
-
CDK4
0.000001
1-methyl-8-[[1-(phenylcarbonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000003
1-methyl-8-[[1-(phenylcarbonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.00008
2-(2-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK1
0.00008
2-(2-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK2
0.00089
2-(2-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK4
0.000007
2-(3-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK2
0.000047
2-(3-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK1
0.0018
2-(3-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK4
0.000034
2-(3-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK1
0.000034
2-(3-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK2
0.00105
2-(3-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK4
0.000016
2-(4-aminophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK2
0.00006
2-(4-aminophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK1
0.0022
2-(4-aminophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK4
0.000007
2-(4-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK2
0.000022
2-(4-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK1
0.002
2-(4-bromophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK4
0.000012
2-(4-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK1
0.000012
2-(4-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK2
0.002
2-(4-chlorophenyl)-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK4
0.000014
2-biphenyl-4-yl-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK2
0.000042
2-biphenyl-4-yl-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK1
0.0022
2-biphenyl-4-yl-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK4
0.00003
2-[(3,4-dimethoxyphenyl)amino]-8-ethylpyrido[2,3-d]pyrimidin-7(8H)-one
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.00054
2-[(3,4-dimethoxyphenyl)amino]-8-ethylpyrido[2,3-d]pyrimidin-7(8H)-one
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk2/cyclin E
0.00004
2-[4-(diethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK2
0.00006
2-[4-(diethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK1
0.001
2-[4-(diethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK4, IC50 above 0.001 mM
0.00001
2-[4-(dimethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK2
0.000028
2-[4-(dimethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK1
0.00021
2-[4-(dimethylamino)phenyl]-N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]acetamide
Homo sapiens
with isozyme CDK4
0.000005
3-isopropyl-5(R)-(2-hydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000021
3-isopropyl-5(R)-(2-hydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000009
3-isopropyl-5(R)-[1-(hydroxymethyl)propyl]amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000054
3-isopropyl-5(R)-[1-(hydroxymethyl)propyl]amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.00145
3-isopropyl-5,7-di[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.0036
3-isopropyl-5,7-di[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000012
3-isopropyl-5-(2,3-dihydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000021
3-isopropyl-5-(2,3-dihydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000008
3-isopropyl-5-(2-aminoethyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000018
3-isopropyl-5-(2-aminoethyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000001
3-isopropyl-5-(2-hydroxy-2-methylpropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000009
3-isopropyl-5-(2-hydroxy-2-methylpropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000031
3-isopropyl-5-(2-hydroxyethyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000049
3-isopropyl-5-(2-hydroxyethyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000017
3-isopropyl-5-(3-amino-2-hydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000051
3-isopropyl-5-(3-amino-2-hydroxypropyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.001486
3-isopropyl-5-(4-methoxybenzyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.004415
3-isopropyl-5-(4-methoxybenzyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000005
3-isopropyl-5-(N-morpholinyl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000018
3-isopropyl-5-(N-morpholinyl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.00005
3-isopropyl-5-(piperazin-1-yl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000119
3-isopropyl-5-(piperazin-1-yl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000061
3-isopropyl-5-(thiomorpholinyl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000114
3-isopropyl-5-(thiomorpholinyl)-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000044
3-isopropyl-5-(trans-2-aminocyclohexyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000046
3-isopropyl-5-(trans-2-aminocyclohexyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000096
3-isopropyl-5-(trans-4-aminocyclohexyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000179
3-isopropyl-5-(trans-4-aminocyclohexyl)amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000048
3-isopropyl-5-methylsulfanyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000229
3-isopropyl-5-methylsulfanyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.00007
3-isopropyl-5-methylsulfonyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000165
3-isopropyl-5-methylsulfonyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000024
3-isopropyl-5-[2-(2-hydroxyethyl)piperidin-1-yl]-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000037
3-isopropyl-5-[2-(2-hydroxyethyl)piperidin-1-yl]-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000467
3-isopropyl-5-[2-(dimethylamino)ethyl]amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.002136
3-isopropyl-5-[2-(dimethylamino)ethyl]amino-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000132
3-isopropyl-5-[4-(2-hydroxyethyl)piperazin-1-yl]-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.000422
3-isopropyl-5-[4-(2-hydroxyethyl)piperazin-1-yl]-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000183
3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.000197
3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.001764
4-(1,3-benzothiazol-2-yl)-N-(1,3-thiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.00548
4-(1,3-benzothiazol-2-yl)-N-(1,3-thiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk2/cyclin E
0.00547
4-(1,3-benzothiazol-2-yl)-N-(pyridin-2-ylmethyl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.00672
4-(1,3-benzothiazol-2-yl)-N-(pyridin-2-ylmethyl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk2/cyclin E
0.000551
4-(1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.0045
4-(1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk2/cyclin E
0.0000008
4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2,3-dihydroxypropyl)-benzenesulfonamide
Homo sapiens
-
-
0.000034
4-(6-amino-4-cyclohexylmethoxy-5-nitrosopyrimidin-2-ylamino)-N-(2,3-dihydroxypropyl)-benzenesulfonamide
Homo sapiens
-
-
0.000355
4-(6-chloro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.00086
4-(6-chloro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk2/cyclin E
0.000331
4-(6-fluoro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.00072
4-(6-fluoro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk2/cyclin E
0.000226
4-(6-methyl-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk2/cyclin E
0.00126
4-(6-methyl-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.000452
4-(6-nitro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk2/cyclin E
0.00127
4-(6-nitro-1,3-benzothiazol-2-yl)thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.000006
4-chloro-N-(cis-3-[4-[(naphthalen-1-ylacetyl)amino]-1H-imidazol-1-yl]cyclobutyl)benzamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.000204
4-chloro-N-(cis-3-[4-[(naphthalen-1-ylacetyl)amino]-1H-imidazol-1-yl]cyclobutyl)benzamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk2/cyclin E
0.000033
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-(4-[[3-(1,3-oxazetidin-3-yl)propyl]sulfonyl]phenyl)pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.00021
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-(4-[[3-(1,3-oxazetidin-3-yl)propyl]sulfonyl]phenyl)pyrimidin-2-amine
Homo sapiens
with CDK4
0.000006
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.00045
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-(methylsulfonyl)phenyl]pyrimidin-2-amine
Homo sapiens
with isozyme CDK4
0.000013
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.00053
4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]-N-[4-[(tetrahydrofuran-2-ylmethyl)sulfonyl]phenyl]pyrimidin-2-amine
Homo sapiens
with CDK4
0.000492
4-[7-(4-chloro-3-fluorophenyl)-1,3-benzothiazol-2-yl]thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk2/cyclin E
0.000672
4-[7-(4-chloro-3-fluorophenyl)-1,3-benzothiazol-2-yl]thiophene-2-sulfonamide
Homo sapiens
pH 7.35, temperature not specified in the publication, inhibition of cdk5/p25
0.000008
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.0056
4-[[4-(1,2-dimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
Homo sapiens
with isozyme CDK4
0.000083
4-[[4-(1-cyclopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.009
4-[[4-(1-cyclopropyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
Homo sapiens
with CDK4, IC50 above 0.009 mM
0.000004
4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.0013
4-[[4-(1-ethyl-2-methyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]-N-(2-methoxyethyl)benzenesulfonamide
Homo sapiens
with CDK4
0.000005
8-(cyclopentylamino)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000006
8-(cyclopentylamino)-1-(2,2,2-trifluoroethyl)-4,5-dihydro-1Hpyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000035
alsterpaullone
Homo sapiens
-
CDK1
0.00004
alsterpaullone
Homo sapiens
-
CDK5
0.0002
alsterpaullone
Homo sapiens
-
CDK2
0.01
alsterpaullone
Homo sapiens
-
IC50 above 0.01 mM, CDK4
0.00002
aminopurvalanol
Homo sapiens
-
CDK5
0.000028
aminopurvalanol
Homo sapiens
-
CDK2
0.000033
aminopurvalanol
Homo sapiens
-
CDK1
0.000021
BS-181
Homo sapiens
-
CDK7
0.00088
BS-181
Homo sapiens
-
CDK2
0.003
BS-181
Homo sapiens
-
CDK5
0.0042
BS-181
Homo sapiens
-
CDK9
0.0081
BS-181
Homo sapiens
-
CDK1
0.033
BS-181
Homo sapiens
-
CDK4
0.047
BS-181
Homo sapiens
-
CDK6
0.0005
CVT-313
Rattus norvegicus
-
IC50 for CDK2 0.0005 mM
0.004
CVT-313
Rattus norvegicus
-
inhibitor used in treatment of neointimal hyperplasia, IC50 for CDK1 is 0.004 mM
0.215
CVT-313
Rattus norvegicus
-
IC50 for CDK4 0.215 mM
0.00035
fascaplysin
Homo sapiens
-
CDK4
0.02
fascaplysin
Homo sapiens
-
CDK5
0.05
fascaplysin
Homo sapiens
-
IC50 above 0.05 mM, CDK2
0.1
fascaplysin
Homo sapiens
-
IC50 above 0.1 mM, CDK1
0.0000052
flavopiridol
Homo sapiens
-
isoform CDK9, at pH 7.5 and 37°C
0.000006
flavopiridol
Homo sapiens
-
CDK9
0.00006
flavopiridol
Rattus norvegicus
-
IC50 for CDK6 0.00006 mM
0.00006
flavopiridol
Homo sapiens
-
CDK1
0.000065
flavopiridol
Rattus norvegicus
-
IC50 for CDK4 0.000065 mM
0.0001
flavopiridol
Rattus norvegicus
-
IC50 for CDK2 0.0001 mM
0.00011 - 0.0003
flavopiridol
Rattus norvegicus
-
IC50 for CDK7 0.00011-0.0003 mM
0.00015
flavopiridol
Homo sapiens
-
CDK2
0.00017
flavopiridol
Homo sapiens
-
CDK5
0.0003
flavopiridol
Homo sapiens
-
CDK7
0.0004
flavopiridol
Homo sapiens
-
CDK4
0.0005
flavopiridol
Rattus norvegicus
-
inhibitor used in treatment of neointimal hyperplasia, IC50 for CDK1 is 0.0005 mM
0.00005
H717
Homo sapiens
-
CDK2
0.00023
H717
Homo sapiens
-
CDK1
0.000022
hymenialdisine
Homo sapiens
-
CDK1
0.000028
hymenialdisine
Homo sapiens
-
CDK5
0.00004
hymenialdisine
Homo sapiens
-
CDK2
0.0006
hymenialdisine
Homo sapiens
-
CDK4
0.000026
meriolin
Homo sapiens
-
CDK9
0.00009
meriolin
Homo sapiens
-
CDK2
0.00051
meriolin
Homo sapiens
-
CDK5
0.00078
meriolin
Homo sapiens
-
CDK1
0.000001
N-(2-methoxyethyl)-4-([4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino)benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.0002
N-(2-methoxyethyl)-4-([4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-yl]amino)benzenesulfonamide
Homo sapiens
with CDK4
0.00068
N-(2-methoxyethyl)-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
Homo sapiens
with isozyme CDK2
0.0086
N-(2-methoxyethyl)-4-[[4-(1,2,4-trimethyl-1H-imidazol-5-yl)pyrimidin-2-yl]amino]benzenesulfonamide
Homo sapiens
with CDK4, IC50 above 0.0086 mM
0.000036
N-(4-[[3-(dimethylamino)propyl]sulfonyl]phenyl)-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.00014
N-(4-[[3-(dimethylamino)propyl]sulfonyl]phenyl)-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
Homo sapiens
with CDK4
0.000002
N-1-dimethyl-8-[[1-(methylsulfonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000005
N-1-dimethyl-8-[[1-(methylsulfonyl)piperidin-4-yl]amino]-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide
Homo sapiens
-
pH 7.5, 30°C
0.000019
N-[4-(benzylsulfonyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.0015
N-[4-(benzylsulfonyl)phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
Homo sapiens
with CDK4
0.000014
N-[4-[(2-methoxyethyl)sulfonyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
Homo sapiens
with isozyme CDK2
0.00049
N-[4-[(2-methoxyethyl)sulfonyl]phenyl]-4-[2-methyl-1-(1-methylethyl)-1H-imidazol-5-yl]pyrimidin-2-amine
Homo sapiens
with CDK4
0.00003
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-fluorophenyl)acetamide
Homo sapiens
with isozyme CDK1
0.00003
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-fluorophenyl)acetamide
Homo sapiens
with isozyme CDK2
0.00071
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-fluorophenyl)acetamide
Homo sapiens
with isozyme CDK4
0.00001
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-methylphenyl)acetamide
Homo sapiens
with isozyme CDK2
0.00005
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-methylphenyl)acetamide
Homo sapiens
with isozyme CDK1
0.004
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(3-methylphenyl)acetamide
Homo sapiens
with isozyme CDK4
0.00005
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-fluorophenyl)acetamide
Homo sapiens
with isozyme CDK1
0.00005
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-fluorophenyl)acetamide
Homo sapiens
with isozyme CDK2
0.003
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-fluorophenyl)acetamide
Homo sapiens
with isozyme CDK4
0.000009
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-hydroxyphenyl)acetamide
Homo sapiens
with isozyme CDK2
0.000028
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-hydroxyphenyl)acetamide
Homo sapiens
with isozyme CDK1
0.00175
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-hydroxyphenyl)acetamide
Homo sapiens
with isozyme CDK4
0.000007
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-methylphenyl)acetamide
Homo sapiens
with isozyme CDK2
0.00004
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-methylphenyl)acetamide
Homo sapiens
with isozyme CDK1
0.0018
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-methylphenyl)acetamide
Homo sapiens
with isozyme CDK4
0.00003
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-piperidin-1-ylphenyl)acetamide
Homo sapiens
with isozyme CDK2
0.00015
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-piperidin-1-ylphenyl)acetamide
Homo sapiens
with isozyme CDK1
0.00075
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-piperidin-1-ylphenyl)acetamide
Homo sapiens
with isozyme CDK4
0.00003
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-pyridin-4-ylphenyl)acetamide
Homo sapiens
with isozyme CDK2
0.00006
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-pyridin-4-ylphenyl)acetamide
Homo sapiens
with isozyme CDK1
0.00133
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-(4-pyridin-4-ylphenyl)acetamide
Homo sapiens
with isozyme CDK4
0.00002
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-1-ylacetamide
Homo sapiens
with isozyme CDK2
0.000067
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-1-ylacetamide
Homo sapiens
with isozyme CDK1
0.003
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-1-ylacetamide
Homo sapiens
with isozyme CDK4
0.000009
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-2-ylacetamide
Homo sapiens
with isozyme CDK2
0.00004
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-2-ylacetamide
Homo sapiens
with isozyme CDK1
0.0016
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-naphthalen-2-ylacetamide
Homo sapiens
with isozyme CDK4
0.000036
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-phenylacetamide
Homo sapiens
with isozyme CDK2
0.00008
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-phenylacetamide
Homo sapiens
with isozyme CDK1
0.0037
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-phenylacetamide
Homo sapiens
with isozyme CDK4
0.00001
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfanyl)phenyl]acetamide
Homo sapiens
with isozyme CDK2
0.00004
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfanyl)phenyl]acetamide
Homo sapiens
with isozyme CDK1
0.0013
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfanyl)phenyl]acetamide
Homo sapiens
with isozyme CDK4
0.000022
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfonyl)phenyl]acetamide
Homo sapiens
with isozyme CDK2
0.0002
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfonyl)phenyl]acetamide
Homo sapiens
with isozyme CDK1
0.0014
N-[5-(1,1-dioxidoisothiazolidin-2-yl)-1H-indazol-3-yl]-2-[4-(methylsulfonyl)phenyl]acetamide
Homo sapiens
with isozyme CDK4
0.005
NU-2058
Homo sapiens
-
CDK1
0.012
NU-2058
Homo sapiens
-
CDK2
0.0013
NU-6027
Homo sapiens
-
CDK2
0.0025
NU-6027
Homo sapiens
-
CDK1
0.003
Olomoucine
Homo sapiens
-
CDK5
0.007
Olomoucine
Homo sapiens
-
CDK1
0.007
Olomoucine
Homo sapiens
-
CDK2
1
Olomoucine
Homo sapiens
-
IC50 above 1.0 mM, CDK4
0.00006
olomoucine II
Homo sapiens
-
CDK9
0.0001
olomoucine II
Homo sapiens
-
CDK2
0.00045
olomoucine II
Homo sapiens
-
CDK7
0.0076
olomoucine II
Homo sapiens
-
CDK1
0.0198
olomoucine II
Homo sapiens
-
CDK4
0.000008
PD183812
Homo sapiens
-
CDK4
0.00017
PD183812
Homo sapiens
-
CDK2
0.04
PD183812
Homo sapiens
-
IC50 above 0.04 mM, CDK1
0.000006
purvalanol B
Homo sapiens
-
CDK1
0.000006
purvalanol B
Homo sapiens
-
CDK5
0.000009
purvalanol B
Homo sapiens
-
CDK2
0.01
purvalanol B
Homo sapiens
-
IC50 above 0.01 mM, CDK4
0.0001
roscovitine
Homo sapiens
-
CDK2
0.000158
roscovitine
Homo sapiens
-
isoform CDK2, at pH 7.5, temperature not specified in the publication
0.00024
roscovitine
Homo sapiens
-
CDK5
0.00025
roscovitine
Homo sapiens
-
pH 7.5, 37°C
0.00051
roscovitine
Homo sapiens
-
CDK7
0.001069
roscovitine
Homo sapiens
-
isoform CDK5, at pH 7.5, temperature not specified in the publication
0.0012
roscovitine
Homo sapiens
-
CDK9
0.0018
roscovitine
Homo sapiens
-
CDK1
0.0153
roscovitine
Homo sapiens
-
CDK4
0.028
roscovitine
Homo sapiens
-
CDK6
0.000006
staurosporine
Homo sapiens
-
CDK1
0.000007
staurosporine
Homo sapiens
-
CDK2
0.01
staurosporine
Homo sapiens
-
IC50 above 0.01 mM, CDK4
0.00004
SU-9516
Homo sapiens
-
CDK1
0.0002
SU-9516
Homo sapiens
-
CDK4
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.